Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • Search results for:
    • covid 19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [qs] => covid 19
        )

    [filters] => Array
        (
            [text_search] => covid 19
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [post__in] => Array
                (
                    [0] => 9090
                    [1] => 9089
                    [2] => 9088
                    [3] => 9087
                    [4] => 9086
                    [5] => 9083
                    [6] => 9082
                    [7] => 9081
                    [8] => 9080
                    [9] => 9079
                    [10] => 9078
                    [11] => 9077
                    [12] => 9076
                    [13] => 9073
                    [14] => 9072
                    [15] => 9071
                    [16] => 9070
                    [17] => 9069
                    [18] => 9068
                    [19] => 9067
                    [20] => 9066
                    [21] => 9065
                    [22] => 9064
                    [23] => 9063
                    [24] => 9062
                    [25] => 9061
                    [26] => 8462
                    [27] => 8447
                    [28] => 8314
                    [29] => 8313
                    [30] => 8312
                    [31] => 8311
                    [32] => 8192
                    [33] => 8191
                    [34] => 8190
                    [35] => 8157
                    [36] => 8152
                    [37] => 8151
                    [38] => 8150
                    [39] => 8143
                    [40] => 8142
                    [41] => 8131
                    [42] => 8130
                    [43] => 8129
                    [44] => 8051
                    [45] => 5808
                    [46] => 5782
                    [47] => 5653
                    [48] => 5652
                    [49] => 5620
                    [50] => 5619
                    [51] => 5618
                    [52] => 5617
                    [53] => 5616
                    [54] => 5615
                    [55] => 5614
                    [56] => 5612
                    [57] => 5611
                    [58] => 5610
                    [59] => 5609
                    [60] => 5608
                    [61] => 5599
                    [62] => 5596
                    [63] => 5595
                    [64] => 5594
                    [65] => 5593
                    [66] => 5592
                    [67] => 5591
                    [68] => 5429
                    [69] => 5123
                    [70] => 5122
                    [71] => 5121
                    [72] => 5120
                    [73] => 5119
                    [74] => 5118
                    [75] => 5117
                    [76] => 5116
                    [77] => 5115
                    [78] => 5114
                    [79] => 5113
                    [80] => 5112
                    [81] => 5111
                    [82] => 4808
                    [83] => 4807
                    [84] => 4806
                    [85] => 4805
                    [86] => 4804
                    [87] => 4802
                    [88] => 4801
                    [89] => 4800
                    [90] => 4798
                    [91] => 4797
                    [92] => 4796
                    [93] => 4661
                    [94] => 4147
                    [95] => 4601
                    [96] => 4148
                    [97] => 4223
                    [98] => 4222
                    [99] => 4221
                    [100] => 4220
                    [101] => 4219
                    [102] => 4218
                    [103] => 4217
                    [104] => 4216
                    [105] => 4215
                    [106] => 4214
                    [107] => 4213
                    [108] => 4212
                    [109] => 4210
                    [110] => 4209
                    [111] => 4205
                    [112] => 4204
                    [113] => 4201
                    [114] => 4200
                    [115] => 4161
                    [116] => 4159
                    [117] => 4158
                    [118] => 4157
                    [119] => 4156
                    [120] => 4155
                    [121] => 4154
                    [122] => 4153
                    [123] => 4152
                    [124] => 4151
                    [125] => 4150
                    [126] => 4149
                    [127] => 4146
                    [128] => 4141
                    [129] => 4140
                    [130] => 4139
                    [131] => 4138
                    [132] => 4137
                    [133] => 4136
                    [134] => 4135
                    [135] => 4134
                    [136] => 4133
                    [137] => 4131
                    [138] => 4130
                    [139] => 4129
                    [140] => 4128
                    [141] => 4058
                    [142] => 4054
                    [143] => 4051
                    [144] => 4050
                    [145] => 4047
                    [146] => 4046
                    [147] => 4045
                    [148] => 4043
                    [149] => 4042
                    [150] => 4041
                    [151] => 4040
                    [152] => 4038
                    [153] => 4036
                    [154] => 4035
                    [155] => 4032
                    [156] => 4029
                    [157] => 4028
                    [158] => 4024
                    [159] => 4022
                    [160] => 4021
                    [161] => 4020
                    [162] => 4017
                    [163] => 4016
                    [164] => 4014
                    [165] => 4013
                    [166] => 4011
                    [167] => 4009
                    [168] => 4007
                    [169] => 4006
                    [170] => 4004
                    [171] => 4003
                    [172] => 4002
                    [173] => 4001
                    [174] => 3997
                    [175] => 3869
                    [176] => 3886
                    [177] => 3884
                    [178] => 3883
                    [179] => 3882
                    [180] => 3881
                    [181] => 3880
                    [182] => 3878
                    [183] => 3877
                    [184] => 3876
                    [185] => 3875
                    [186] => 3874
                    [187] => 3873
                    [188] => 3870
                    [189] => 3863
                    [190] => 3861
                    [191] => 3860
                    [192] => 3859
                    [193] => 3858
                    [194] => 3857
                    [195] => 3856
                    [196] => 3855
                    [197] => 3854
                    [198] => 3852
                    [199] => 3851
                    [200] => 3849
                    [201] => 3848
                    [202] => 3847
                    [203] => 3846
                    [204] => 3819
                    [205] => 3812
                    [206] => 3810
                    [207] => 3809
                    [208] => 3808
                    [209] => 3807
                    [210] => 3806
                    [211] => 3805
                    [212] => 3804
                    [213] => 3803
                    [214] => 3802
                    [215] => 3801
                    [216] => 3800
                    [217] => 3799
                    [218] => 3798
                    [219] => 3797
                    [220] => 3796
                    [221] => 3792
                    [222] => 3791
                    [223] => 3789
                    [224] => 3788
                    [225] => 3786
                    [226] => 3784
                    [227] => 3783
                    [228] => 3782
                    [229] => 3781
                    [230] => 3778
                    [231] => 3765
                    [232] => 3764
                    [233] => 3758
                    [234] => 3741
                    [235] => 3696
                    [236] => 3495
                    [237] => 3493
                    [238] => 3436
                    [239] => 3434
                    [240] => 3433
                    [241] => 3431
                    [242] => 3430
                    [243] => 3428
                    [244] => 3427
                    [245] => 3426
                    [246] => 3424
                    [247] => 3422
                    [248] => 3421
                    [249] => 3420
                    [250] => 3372
                    [251] => 3370
                    [252] => 3368
                    [253] => 3366
                    [254] => 3364
                    [255] => 3361
                    [256] => 3360
                    [257] => 3356
                    [258] => 3354
                    [259] => 3352
                    [260] => 3221
                    [261] => 3220
                    [262] => 3219
                    [263] => 3218
                    [264] => 3217
                    [265] => 3215
                    [266] => 3127
                    [267] => 3126
                    [268] => 3125
                    [269] => 3124
                    [270] => 3123
                    [271] => 3122
                    [272] => 3121
                    [273] => 3120
                    [274] => 3119
                    [275] => 2956
                    [276] => 2961
                    [277] => 2965
                    [278] => 2947
                    [279] => 2960
                    [280] => 2964
                    [281] => 2958
                    [282] => 2949
                    [283] => 2957
                    [284] => 2962
                    [285] => 2945
                    [286] => 2909
                    [287] => 2908
                    [288] => 2907
                    [289] => 2893
                    [290] => 2892
                    [291] => 2890
                    [292] => 2889
                    [293] => 2885
                    [294] => 2824
                    [295] => 2822
                    [296] => 2820
                    [297] => 2744
                    [298] => 2749
                    [299] => 2748
                    [300] => 2743
                    [301] => 2742
                    [302] => 2741
                    [303] => 2739
                    [304] => 2737
                    [305] => 2736
                    [306] => 2734
                    [307] => 2543
                    [308] => 2540
                    [309] => 2541
                    [310] => 2542
                    [311] => 2544
                    [312] => 2545
                    [313] => 2547
                    [314] => 2549
                    [315] => 2553
                    [316] => 2457
                    [317] => 2461
                    [318] => 2462
                    [319] => 2463
                    [320] => 2464
                    [321] => 2465
                    [322] => 2466
                    [323] => 2467
                    [324] => 2470
                    [325] => 2473
                    [326] => 2474
                    [327] => 2475
                    [328] => 2476
                    [329] => 2477
                    [330] => 2479
                    [331] => 2481
                    [332] => 2482
                    [333] => 2471
                    [334] => 2452
                    [335] => 2450
                    [336] => 2449
                    [337] => 2448
                    [338] => 2444
                    [339] => 2443
                    [340] => 2442
                    [341] => 2441
                    [342] => 2426
                    [343] => 2424
                    [344] => 9090
                    [345] => 9089
                    [346] => 9088
                    [347] => 9087
                    [348] => 9086
                    [349] => 9083
                    [350] => 9082
                    [351] => 9081
                    [352] => 9080
                    [353] => 9079
                    [354] => 9078
                    [355] => 9077
                    [356] => 9076
                    [357] => 9073
                    [358] => 9072
                    [359] => 9071
                    [360] => 9070
                    [361] => 9069
                    [362] => 9068
                    [363] => 9067
                    [364] => 9066
                    [365] => 9065
                    [366] => 9064
                    [367] => 9063
                    [368] => 9062
                    [369] => 9061
                    [370] => 8462
                    [371] => 8447
                    [372] => 8314
                    [373] => 8313
                    [374] => 8312
                    [375] => 8311
                    [376] => 8192
                    [377] => 8191
                    [378] => 8190
                    [379] => 8157
                    [380] => 8152
                    [381] => 8151
                    [382] => 8150
                    [383] => 8143
                    [384] => 8142
                    [385] => 8131
                    [386] => 8130
                    [387] => 8129
                    [388] => 8051
                    [389] => 5808
                    [390] => 5782
                    [391] => 5653
                    [392] => 5652
                    [393] => 5620
                    [394] => 5619
                    [395] => 5618
                    [396] => 5617
                    [397] => 5616
                    [398] => 5615
                    [399] => 5614
                    [400] => 5612
                    [401] => 5611
                    [402] => 5610
                    [403] => 5609
                    [404] => 5608
                    [405] => 5599
                    [406] => 5596
                    [407] => 5595
                    [408] => 5594
                    [409] => 5593
                    [410] => 5592
                    [411] => 5591
                    [412] => 5429
                    [413] => 5123
                    [414] => 5122
                    [415] => 5121
                    [416] => 5120
                    [417] => 5119
                    [418] => 5118
                    [419] => 5117
                    [420] => 5116
                    [421] => 5115
                    [422] => 5114
                    [423] => 5113
                    [424] => 5112
                    [425] => 5111
                    [426] => 4808
                    [427] => 4807
                    [428] => 4806
                    [429] => 4805
                    [430] => 4804
                    [431] => 4802
                    [432] => 4801
                    [433] => 4800
                    [434] => 4798
                    [435] => 4797
                    [436] => 4796
                    [437] => 4661
                    [438] => 4147
                    [439] => 4601
                    [440] => 4148
                    [441] => 4223
                    [442] => 4222
                    [443] => 4221
                    [444] => 4220
                    [445] => 4219
                    [446] => 4218
                    [447] => 4217
                    [448] => 4216
                    [449] => 4215
                    [450] => 4214
                    [451] => 4213
                    [452] => 4212
                    [453] => 4210
                    [454] => 4209
                    [455] => 4205
                    [456] => 4204
                    [457] => 4201
                    [458] => 4200
                    [459] => 4161
                    [460] => 4159
                    [461] => 4158
                    [462] => 4157
                    [463] => 4156
                    [464] => 4155
                    [465] => 4154
                    [466] => 4153
                    [467] => 4152
                    [468] => 4151
                    [469] => 4150
                    [470] => 4149
                    [471] => 4146
                    [472] => 4141
                    [473] => 4140
                    [474] => 4139
                    [475] => 4138
                    [476] => 4137
                    [477] => 4136
                    [478] => 4135
                    [479] => 4134
                    [480] => 4133
                    [481] => 4131
                    [482] => 4130
                    [483] => 4129
                    [484] => 4128
                    [485] => 4058
                    [486] => 4054
                    [487] => 4051
                    [488] => 4050
                    [489] => 4047
                    [490] => 4046
                    [491] => 4045
                    [492] => 4043
                    [493] => 4042
                    [494] => 4041
                    [495] => 4040
                    [496] => 4038
                    [497] => 4036
                    [498] => 4035
                    [499] => 4032
                    [500] => 4029
                    [501] => 4028
                    [502] => 4024
                    [503] => 4022
                    [504] => 4021
                    [505] => 4020
                    [506] => 4017
                    [507] => 4016
                    [508] => 4014
                    [509] => 4013
                    [510] => 4011
                    [511] => 4009
                    [512] => 4007
                    [513] => 4006
                    [514] => 4004
                    [515] => 4003
                    [516] => 4002
                    [517] => 4001
                    [518] => 3997
                    [519] => 3869
                    [520] => 3886
                    [521] => 3884
                    [522] => 3883
                    [523] => 3882
                    [524] => 3881
                    [525] => 3880
                    [526] => 3878
                    [527] => 3877
                    [528] => 3876
                    [529] => 3875
                    [530] => 3874
                    [531] => 3873
                    [532] => 3870
                    [533] => 3863
                    [534] => 3861
                    [535] => 3860
                    [536] => 3859
                    [537] => 3858
                    [538] => 3857
                    [539] => 3856
                    [540] => 3855
                    [541] => 3854
                    [542] => 3852
                    [543] => 3851
                    [544] => 3849
                    [545] => 3848
                    [546] => 3847
                    [547] => 3846
                    [548] => 3819
                    [549] => 3812
                    [550] => 3810
                    [551] => 3809
                    [552] => 3808
                    [553] => 3807
                    [554] => 3806
                    [555] => 3805
                    [556] => 3804
                    [557] => 3803
                    [558] => 3802
                    [559] => 3801
                    [560] => 3800
                    [561] => 3799
                    [562] => 3798
                    [563] => 3797
                    [564] => 3796
                    [565] => 3792
                    [566] => 3791
                    [567] => 3789
                    [568] => 3788
                    [569] => 3786
                    [570] => 3784
                    [571] => 3783
                    [572] => 3782
                    [573] => 3781
                    [574] => 3778
                    [575] => 3765
                    [576] => 3764
                    [577] => 3758
                    [578] => 3741
                    [579] => 3696
                    [580] => 3495
                    [581] => 3493
                    [582] => 3436
                    [583] => 3434
                    [584] => 3433
                    [585] => 3431
                    [586] => 3430
                    [587] => 3428
                    [588] => 3427
                    [589] => 3426
                    [590] => 3424
                    [591] => 3422
                    [592] => 3421
                    [593] => 3420
                    [594] => 3372
                    [595] => 3370
                    [596] => 3368
                    [597] => 3366
                    [598] => 3364
                    [599] => 3361
                    [600] => 3360
                    [601] => 3356
                    [602] => 3354
                    [603] => 3352
                    [604] => 3221
                    [605] => 3220
                    [606] => 3219
                    [607] => 3218
                    [608] => 3217
                    [609] => 3215
                    [610] => 3127
                    [611] => 3126
                    [612] => 3125
                    [613] => 3124
                    [614] => 3123
                    [615] => 3122
                    [616] => 3121
                    [617] => 3120
                    [618] => 3119
                    [619] => 2956
                    [620] => 2961
                    [621] => 2965
                    [622] => 2947
                    [623] => 2960
                    [624] => 2964
                    [625] => 2958
                    [626] => 2949
                    [627] => 2957
                    [628] => 2962
                    [629] => 2945
                    [630] => 2909
                    [631] => 2908
                    [632] => 2907
                    [633] => 2893
                    [634] => 2892
                    [635] => 2890
                    [636] => 2889
                    [637] => 2885
                    [638] => 2824
                    [639] => 2822
                    [640] => 2820
                    [641] => 2744
                    [642] => 2749
                    [643] => 2748
                    [644] => 2743
                    [645] => 2742
                    [646] => 2741
                    [647] => 2739
                    [648] => 2737
                    [649] => 2736
                    [650] => 2734
                    [651] => 2543
                    [652] => 2540
                    [653] => 2541
                    [654] => 2542
                    [655] => 2544
                    [656] => 2545
                    [657] => 2547
                    [658] => 2549
                    [659] => 2553
                    [660] => 2457
                    [661] => 2461
                    [662] => 2462
                    [663] => 2463
                    [664] => 2464
                    [665] => 2465
                    [666] => 2466
                    [667] => 2467
                    [668] => 2470
                    [669] => 2473
                    [670] => 2474
                    [671] => 2475
                    [672] => 2476
                    [673] => 2477
                    [674] => 2479
                    [675] => 2481
                    [676] => 2482
                    [677] => 2471
                    [678] => 2452
                    [679] => 2450
                    [680] => 2449
                    [681] => 2448
                    [682] => 2444
                    [683] => 2443
                    [684] => 2442
                    [685] => 2441
                    [686] => 2426
                    [687] => 2424
                    [688] => 3910
                    [689] => 3909
                    [690] => 3908
                    [691] => 3907
                    [692] => 3906
                    [693] => 3904
                    [694] => 3903
                    [695] => 3901
                    [696] => 3900
                    [697] => 3899
                    [698] => 3898
                    [699] => 3897
                    [700] => 3896
                    [701] => 3895
                    [702] => 3892
                    [703] => 3891
                    [704] => 3418
                    [705] => 3417
                    [706] => 3416
                    [707] => 3415
                    [708] => 3414
                    [709] => 3413
                    [710] => 3412
                    [711] => 3411
                    [712] => 3410
                    [713] => 3406
                    [714] => 3304
                    [715] => 2873
                    [716] => 2872
                    [717] => 2870
                    [718] => 2869
                    [719] => 2867
                )

        )

    [text_agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [s] => covid 19
        )

    [text_provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [s] => covid 19
        )

    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => 
    [text_agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => covid 19
                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => covid 19
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 2
                    [search_terms] => Array
                        (
                            [0] => covid
                            [1] => 19
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}'
                            [1] => wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}'
                        )

                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => 
			SELECT DISTINCT   wpry_posts.*
			FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
			WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) )  AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			
			ORDER BY wpry_posts.post_title ASC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 2438
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:43:39
                            [post_date_gmt] => 2021-01-19 06:43:39
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:05:25
                            [post_modified_gmt] => 2021-09-15 12:05:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 4207
                            [post_author] => 5
                            [post_date] => 2022-03-02 11:38:41
                            [post_date_gmt] => 2022-03-02 11:38:41
                            [post_content] => 
                            [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-02 11:38:51
                            [post_modified_gmt] => 2022-03-02 11:38:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4207
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 4126
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:33:11
                            [post_date_gmt] => 2022-01-28 13:33:11
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-28 13:33:11
                            [post_modified_gmt] => 2022-01-28 13:33:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4126
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:31
                            [post_modified_gmt] => 2021-09-15 11:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 8049
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:37:47
                            [post_date_gmt] => 2022-12-12 08:37:47
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 08:37:47
                            [post_modified_gmt] => 2022-12-12 08:37:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=8049
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 4794
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:39
                            [post_date_gmt] => 2022-05-23 13:54:39
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-23 13:54:39
                            [post_modified_gmt] => 2022-05-23 13:54:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4794
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 3817
                            [post_author] => 6
                            [post_date] => 2021-09-15 10:46:18
                            [post_date_gmt] => 2021-09-15 10:46:18
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:16:37
                            [post_modified_gmt] => 2022-10-11 12:16:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3117
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:15:12
                            [post_date_gmt] => 2021-06-03 14:15:12
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:00:38
                            [post_modified_gmt] => 2021-09-15 12:00:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3117
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 2538
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:41:11
                            [post_date_gmt] => 2021-03-12 13:41:11
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:05:41
                            [post_modified_gmt] => 2021-09-15 12:05:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2538
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 2468
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:15:43
                            [post_date_gmt] => 2021-02-25 15:15:43
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:00:56
                            [post_modified_gmt] => 2021-09-15 12:00:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2468
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 3419
                            [post_author] => 6
                            [post_date] => 2021-07-01 01:45:34
                            [post_date_gmt] => 2021-07-01 01:45:34
                            [post_content] => 
                            [post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-10 18:22:02
                            [post_modified_gmt] => 2021-11-10 18:22:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3419
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 3843
                            [post_author] => 5
                            [post_date] => 2021-11-05 10:54:08
                            [post_date_gmt] => 2021-11-05 10:54:08
                            [post_content] => 
                            [post_title] => Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-05 10:54:08
                            [post_modified_gmt] => 2021-11-05 10:54:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3843
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 5586
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:34:02
                            [post_date_gmt] => 2022-08-11 09:34:02
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:37:27
                            [post_modified_gmt] => 2022-08-11 09:37:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5586
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 5589
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:35:21
                            [post_date_gmt] => 2022-08-11 09:35:21
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:35:21
                            [post_modified_gmt] => 2022-08-11 09:35:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5589
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 4142
                            [post_author] => 5
                            [post_date] => 2022-02-01 18:56:28
                            [post_date_gmt] => 2022-02-01 18:56:28
                            [post_content] => 
                            [post_title] => Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-02 07:30:00
                            [post_modified_gmt] => 2022-02-02 07:30:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4142
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 3867
                            [post_author] => 5
                            [post_date] => 2021-11-18 12:26:40
                            [post_date_gmt] => 2021-11-18 12:26:40
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 12:26:40
                            [post_modified_gmt] => 2021-11-18 12:26:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3867
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 9058
                            [post_author] => 5
                            [post_date] => 2023-03-06 11:20:36
                            [post_date_gmt] => 2023-03-06 11:20:36
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:33:14
                            [post_modified_gmt] => 2023-03-08 11:33:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9058
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 9074
                            [post_author] => 5
                            [post_date] => 2023-03-07 13:56:00
                            [post_date_gmt] => 2023-03-07 13:56:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-07 13:56:00
                            [post_modified_gmt] => 2023-03-07 13:56:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9074
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 5110
                            [post_author] => 5
                            [post_date] => 2022-06-29 11:57:22
                            [post_date_gmt] => 2022-06-29 11:57:22
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 11:57:22
                            [post_modified_gmt] => 2022-06-29 11:57:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5110
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 3794
                            [post_author] => 5
                            [post_date] => 2021-09-10 08:02:49
                            [post_date_gmt] => 2021-09-10 08:02:49
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-02-20 13:22:55
                            [post_modified_gmt] => 2023-02-20 13:22:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3794
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 4026
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:36:17
                            [post_date_gmt] => 2021-12-21 11:36:17
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:01
                            [post_modified_gmt] => 2022-10-11 12:21:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4026
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 3213
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:04:36
                            [post_date_gmt] => 2021-06-28 12:04:36
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:03:12
                            [post_modified_gmt] => 2021-09-15 12:03:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3213
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 2420
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:07
                            [post_date_gmt] => 2020-12-14 14:59:07
                            [post_content] => 
                            [post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:49
                            [post_modified_gmt] => 2022-10-11 12:21:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2420
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 2943
                            [post_author] => 6
                            [post_date] => 2021-05-28 13:48:32
                            [post_date_gmt] => 2021-05-28 13:48:32
                            [post_content] => 
                            [post_title] => UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:12:31
                            [post_modified_gmt] => 2021-09-15 12:12:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2943
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 2817
                            [post_author] => 5
                            [post_date] => 2021-04-16 11:58:45
                            [post_date_gmt] => 2021-04-16 11:58:45
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-23 06:24:06
                            [post_modified_gmt] => 2022-06-23 06:24:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 3776
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:24:04
                            [post_date_gmt] => 2021-09-09 11:24:04
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:12:55
                            [post_modified_gmt] => 2021-09-15 12:12:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3776
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 2446
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:42:42
                            [post_date_gmt] => 2021-01-19 09:42:42
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:03:43
                            [post_modified_gmt] => 2021-09-15 12:03:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2446
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 2732
                            [post_author] => 5
                            [post_date] => 2021-03-23 15:54:07
                            [post_date_gmt] => 2021-03-23 15:54:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:18:39
                            [post_modified_gmt] => 2021-09-15 12:18:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2732
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 2455
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:19:51
                            [post_date_gmt] => 2021-02-25 15:19:51
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:13:19
                            [post_modified_gmt] => 2021-09-15 12:13:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2455
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 3348
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:13:40
                            [post_date_gmt] => 2021-06-30 13:13:40
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:46:12
                            [post_modified_gmt] => 2022-10-12 13:46:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3348
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 30
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 2438
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:43:39
                    [post_date_gmt] => 2021-01-19 06:43:39
                    [post_content] => 
                    [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-15 12:05:25
                    [post_modified_gmt] => 2021-09-15 12:05:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 30
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 9ad98a06ed771fb08875e41e9eaea649
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => covid 19
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => covid 19
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 2
                    [search_terms] => Array
                        (
                            [0] => covid
                            [1] => 19
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}'
                            [1] => wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}'
                        )

                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => 
			SELECT DISTINCT   wpry_posts.*
			FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
			WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) )  AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			
			ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid 19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' THEN 1 WHEN wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' AND wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' THEN 2 WHEN wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' OR wpry_posts.post_title LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' THEN 3 WHEN wpry_posts.post_excerpt LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid 19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' THEN 4 WHEN wpry_posts.post_content LIKE '{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}covid 19{5490ca3fdfff5ec8dfde1ead0bde51eed57b0225f7557f389078713de6475e9f}' THEN 5 ELSE 6 END), wpry_posts.post_date DESC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 9090
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:46:30
                            [post_date_gmt] => 2023-03-08 10:46:30
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:14:44
                            [post_modified_gmt] => 2023-03-08 11:14:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9090
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 9089
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:34:53
                            [post_date_gmt] => 2023-03-08 10:34:53
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:24:52
                            [post_modified_gmt] => 2023-03-08 11:24:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 9088
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:31:00
                            [post_date_gmt] => 2023-03-08 10:31:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 10:31:00
                            [post_modified_gmt] => 2023-03-08 10:31:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9088
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 9087
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:15:07
                            [post_date_gmt] => 2023-03-08 10:15:07
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 10:15:07
                            [post_modified_gmt] => 2023-03-08 10:15:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9087
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 9086
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:59:11
                            [post_date_gmt] => 2023-03-08 09:59:11
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:16:01
                            [post_modified_gmt] => 2023-03-08 12:16:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 9083
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:45:42
                            [post_date_gmt] => 2023-03-08 09:45:42
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:15:35
                            [post_modified_gmt] => 2023-03-08 11:15:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 9082
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:34:23
                            [post_date_gmt] => 2023-03-08 09:34:23
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:17:32
                            [post_modified_gmt] => 2023-03-08 11:17:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 9081
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:59:57
                            [post_date_gmt] => 2023-03-07 14:59:57
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:19:49
                            [post_modified_gmt] => 2023-03-08 11:19:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 9080
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:44:45
                            [post_date_gmt] => 2023-03-07 14:44:45
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:20:27
                            [post_modified_gmt] => 2023-03-08 11:20:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9080
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 9079
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:40:00
                            [post_date_gmt] => 2023-03-07 14:40:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:33:10
                            [post_modified_gmt] => 2023-05-01 14:33:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9079
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 9078
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:31:51
                            [post_date_gmt] => 2023-03-07 14:31:51
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:23:22
                            [post_modified_gmt] => 2023-03-08 11:23:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 9077
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:28:57
                            [post_date_gmt] => 2023-03-07 14:28:57
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:21:30
                            [post_modified_gmt] => 2023-03-08 11:21:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9077
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 9076
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:09:37
                            [post_date_gmt] => 2023-03-07 14:09:37
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:22:36
                            [post_modified_gmt] => 2023-03-08 11:22:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9076
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 9073
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:46:52
                            [post_date_gmt] => 2023-03-07 12:46:52
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:18:23
                            [post_modified_gmt] => 2023-03-08 12:18:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9073
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 9072
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:24:17
                            [post_date_gmt] => 2023-03-07 12:24:17
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:19:29
                            [post_modified_gmt] => 2023-03-08 12:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9072
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 9071
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:09:50
                            [post_date_gmt] => 2023-03-07 12:09:50
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:16:59
                            [post_modified_gmt] => 2023-03-08 12:16:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9071
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 9070
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:39:51
                            [post_date_gmt] => 2023-03-06 18:39:51
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:16:23
                            [post_modified_gmt] => 2023-03-08 12:16:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9070
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 9069
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:34:47
                            [post_date_gmt] => 2023-03-06 18:34:47
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:15:26
                            [post_modified_gmt] => 2023-03-08 12:15:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9069
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 9068
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:20:18
                            [post_date_gmt] => 2023-03-06 18:20:18
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:35:08
                            [post_modified_gmt] => 2023-03-08 11:35:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 9067
                            [post_author] => 5
                            [post_date] => 2023-03-06 16:40:37
                            [post_date_gmt] => 2023-03-06 16:40:37
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:36:48
                            [post_modified_gmt] => 2023-03-08 11:36:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9067
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 9066
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:55:39
                            [post_date_gmt] => 2023-03-06 15:55:39
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:38:10
                            [post_modified_gmt] => 2023-03-08 11:38:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9066
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 9065
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:36:15
                            [post_date_gmt] => 2023-03-06 15:36:15
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:13:07
                            [post_modified_gmt] => 2023-03-08 12:13:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9065
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 9064
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:24:23
                            [post_date_gmt] => 2023-03-06 15:24:23
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:32:16
                            [post_modified_gmt] => 2023-05-01 14:32:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9064
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 9063
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:10:08
                            [post_date_gmt] => 2023-03-06 15:10:08
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:14:56
                            [post_modified_gmt] => 2023-03-08 12:14:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9063
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 9062
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:05:13
                            [post_date_gmt] => 2023-03-06 15:05:13
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:33:55
                            [post_modified_gmt] => 2023-03-08 11:33:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9062
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 9061
                            [post_author] => 5
                            [post_date] => 2023-03-06 13:14:19
                            [post_date_gmt] => 2023-03-06 13:14:19
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:14:30
                            [post_modified_gmt] => 2023-03-08 12:14:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 8462
                            [post_author] => 5
                            [post_date] => 2023-01-10 12:12:52
                            [post_date_gmt] => 2023-01-10 12:12:52
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-29 08:30:22
                            [post_modified_gmt] => 2023-03-29 08:30:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 8447
                            [post_author] => 5
                            [post_date] => 2022-12-15 15:33:22
                            [post_date_gmt] => 2022-12-15 15:33:22
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:33:22
                            [post_modified_gmt] => 2022-12-15 15:33:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8447
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 8314
                            [post_author] => 5
                            [post_date] => 2022-12-13 11:46:36
                            [post_date_gmt] => 2022-12-13 11:46:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 13:02:14
                            [post_modified_gmt] => 2023-04-27 13:02:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 8313
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:48:56
                            [post_date_gmt] => 2022-12-13 10:48:56
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 10:48:56
                            [post_modified_gmt] => 2022-12-13 10:48:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 8312
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:35:08
                            [post_date_gmt] => 2022-12-13 10:35:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:46:26
                            [post_modified_gmt] => 2023-03-30 14:46:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 8311
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:09:44
                            [post_date_gmt] => 2022-12-13 10:09:44
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:43:46
                            [post_modified_gmt] => 2023-03-30 14:43:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 8192
                            [post_author] => 5
                            [post_date] => 2022-12-13 09:04:26
                            [post_date_gmt] => 2022-12-13 09:04:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 09:05:52
                            [post_modified_gmt] => 2022-12-13 09:05:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 8191
                            [post_author] => 5
                            [post_date] => 2022-12-12 16:19:19
                            [post_date_gmt] => 2022-12-12 16:19:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:55:07
                            [post_modified_gmt] => 2022-12-13 12:55:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 8190
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:29:46
                            [post_date_gmt] => 2022-12-12 15:29:46
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:05:30
                            [post_modified_gmt] => 2022-12-14 13:05:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 8157
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:23:50
                            [post_date_gmt] => 2022-12-12 15:23:50
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 16:01:23
                            [post_modified_gmt] => 2023-04-04 16:01:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 8152
                            [post_author] => 5
                            [post_date] => 2022-12-12 12:04:21
                            [post_date_gmt] => 2022-12-12 12:04:21
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:56:37
                            [post_modified_gmt] => 2022-12-13 12:56:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 8151
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:56:08
                            [post_date_gmt] => 2022-12-12 11:56:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 16:02:18
                            [post_modified_gmt] => 2023-04-04 16:02:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 8150
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:21:26
                            [post_date_gmt] => 2022-12-12 11:21:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 11:48:09
                            [post_modified_gmt] => 2022-12-12 11:48:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 8143
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:10:19
                            [post_date_gmt] => 2022-12-12 11:10:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 11:10:19
                            [post_modified_gmt] => 2022-12-12 11:10:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 8142
                            [post_author] => 5
                            [post_date] => 2022-12-12 10:40:31
                            [post_date_gmt] => 2022-12-12 10:40:31
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:57:50
                            [post_modified_gmt] => 2022-12-13 12:57:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 8131
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:57:36
                            [post_date_gmt] => 2022-12-12 09:57:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:38:50
                            [post_modified_gmt] => 2023-04-28 13:38:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 8130
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:34:49
                            [post_date_gmt] => 2022-12-12 09:34:49
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:45:50
                            [post_modified_gmt] => 2023-03-30 14:45:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 8129
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:55:53
                            [post_date_gmt] => 2022-12-12 08:55:53
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 13:48:02
                            [post_modified_gmt] => 2023-05-05 13:48:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 8051
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:39:19
                            [post_date_gmt] => 2022-12-12 08:39:19
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 13:54:45
                            [post_modified_gmt] => 2023-01-10 13:54:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 5808
                            [post_author] => 5
                            [post_date] => 2022-10-04 10:04:03
                            [post_date_gmt] => 2022-10-04 10:04:03
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-04 10:04:03
                            [post_modified_gmt] => 2022-10-04 10:04:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 5782
                            [post_author] => 5
                            [post_date] => 2022-09-16 07:28:56
                            [post_date_gmt] => 2022-09-16 07:28:56
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:42:10
                            [post_modified_gmt] => 2023-03-30 14:42:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 5653
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:56:30
                            [post_date_gmt] => 2022-08-25 12:56:30
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:41:50
                            [post_modified_gmt] => 2023-03-30 14:41:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 5652
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:26:53
                            [post_date_gmt] => 2022-08-25 12:26:53
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:46:10
                            [post_modified_gmt] => 2023-01-10 11:46:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 5620
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:05:12
                            [post_date_gmt] => 2022-08-12 12:05:12
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 12:05:12
                            [post_modified_gmt] => 2022-08-12 12:05:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5620
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 5619
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:02:21
                            [post_date_gmt] => 2022-08-12 12:02:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:01
                            [post_modified_gmt] => 2022-10-12 12:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5619
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 5618
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:52:17
                            [post_date_gmt] => 2022-08-12 11:52:17
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:52:17
                            [post_modified_gmt] => 2022-08-12 11:52:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5618
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 5617
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:49:46
                            [post_date_gmt] => 2022-08-12 11:49:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:49:46
                            [post_modified_gmt] => 2022-08-12 11:49:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5617
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 5616
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:45:22
                            [post_date_gmt] => 2022-08-12 11:45:22
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:45:22
                            [post_modified_gmt] => 2022-08-12 11:45:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5616
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 5615
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:40:08
                            [post_date_gmt] => 2022-08-12 11:40:08
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:40:08
                            [post_modified_gmt] => 2022-08-12 11:40:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5615
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 5614
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:34:41
                            [post_date_gmt] => 2022-08-12 11:34:41
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:28:05
                            [post_modified_gmt] => 2022-09-29 11:28:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5614
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 5612
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:14:31
                            [post_date_gmt] => 2022-08-12 10:14:31
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:42:46
                            [post_modified_gmt] => 2022-12-14 13:42:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5612
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 5611
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:05:33
                            [post_date_gmt] => 2022-08-12 10:05:33
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 10:05:33
                            [post_modified_gmt] => 2022-08-12 10:05:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5611
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 5610
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:31:00
                            [post_date_gmt] => 2022-08-12 09:31:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-28 14:10:06
                            [post_modified_gmt] => 2023-03-28 14:10:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5610
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 5609
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:24:43
                            [post_date_gmt] => 2022-08-12 09:24:43
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 09:24:43
                            [post_modified_gmt] => 2022-08-12 09:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5609
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 5608
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:09:54
                            [post_date_gmt] => 2022-08-12 09:09:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 08:36:41
                            [post_modified_gmt] => 2023-04-27 08:36:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5608
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 5599
                            [post_author] => 5
                            [post_date] => 2022-08-11 14:17:45
                            [post_date_gmt] => 2022-08-11 14:17:45
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:23:07
                            [post_modified_gmt] => 2023-05-01 14:23:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5599
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 5596
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:52:07
                            [post_date_gmt] => 2022-08-11 12:52:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 18:52:16
                            [post_modified_gmt] => 2022-11-08 18:52:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5596
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 5595
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:36:15
                            [post_date_gmt] => 2022-08-11 12:36:15
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:36:15
                            [post_modified_gmt] => 2022-08-11 12:36:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5595
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 5594
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:13:32
                            [post_date_gmt] => 2022-08-11 12:13:32
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:22:41
                            [post_modified_gmt] => 2023-05-01 14:22:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5594
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 5593
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:48:52
                            [post_date_gmt] => 2022-08-11 11:48:52
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:26:53
                            [post_modified_gmt] => 2022-08-11 12:26:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5593
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 5592
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:16:19
                            [post_date_gmt] => 2022-08-11 11:16:19
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:12:08
                            [post_modified_gmt] => 2022-10-13 13:12:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5592
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 5591
                            [post_author] => 5
                            [post_date] => 2022-08-11 10:18:46
                            [post_date_gmt] => 2022-08-11 10:18:46
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 10:18:46
                            [post_modified_gmt] => 2022-08-11 10:18:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5591
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 5429
                            [post_author] => 5
                            [post_date] => 2022-07-25 06:51:00
                            [post_date_gmt] => 2022-07-25 06:51:00
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 12:00:45
                            [post_modified_gmt] => 2023-05-04 12:00:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5429
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 5123
                            [post_author] => 5
                            [post_date] => 2022-06-29 15:28:35
                            [post_date_gmt] => 2022-06-29 15:28:35
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:27:11
                            [post_modified_gmt] => 2023-04-05 12:27:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 5122
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:42:34
                            [post_date_gmt] => 2022-06-29 14:42:34
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 5122
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:03:44
                            [post_modified_gmt] => 2022-10-12 11:03:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 5121
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:38:19
                            [post_date_gmt] => 2022-06-29 14:38:19
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:21:33
                            [post_modified_gmt] => 2023-04-05 12:21:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 5120
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:30:21
                            [post_date_gmt] => 2022-06-29 14:30:21
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:30:21
                            [post_modified_gmt] => 2022-06-29 14:30:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 5119
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:09:28
                            [post_date_gmt] => 2022-06-29 14:09:28
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:09:28
                            [post_modified_gmt] => 2022-06-29 14:09:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 5118
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:05:52
                            [post_date_gmt] => 2022-06-29 14:05:52
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:21:18
                            [post_modified_gmt] => 2023-04-05 12:21:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 5117
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:02:42
                            [post_date_gmt] => 2022-06-29 14:02:42
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:02:42
                            [post_modified_gmt] => 2022-06-29 14:02:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 5116
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:00:58
                            [post_date_gmt] => 2022-06-29 14:00:58
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:00:58
                            [post_modified_gmt] => 2022-06-29 14:00:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5116
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 5115
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:52:08
                            [post_date_gmt] => 2022-06-29 13:52:08
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:53
                            [post_modified_gmt] => 2022-10-12 12:48:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5115
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 5114
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:46:01
                            [post_date_gmt] => 2022-06-29 13:46:01
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 15:10:31
                            [post_modified_gmt] => 2022-06-29 15:10:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 5113
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:33:56
                            [post_date_gmt] => 2022-06-29 13:33:56
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 12:38:36
                            [post_modified_gmt] => 2023-03-21 12:38:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 5112
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:04:55
                            [post_date_gmt] => 2022-06-29 13:04:55
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:33:12
                            [post_modified_gmt] => 2022-07-13 13:33:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 5111
                            [post_author] => 5
                            [post_date] => 2022-06-29 12:40:35
                            [post_date_gmt] => 2022-06-29 12:40:35
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:19:57
                            [post_modified_gmt] => 2023-04-05 12:19:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 4808
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:09:54
                            [post_date_gmt] => 2022-05-24 09:09:54
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:40:46
                            [post_modified_gmt] => 2023-04-28 13:40:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 4807
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:02:55
                            [post_date_gmt] => 2022-05-24 09:02:55
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 09:02:55
                            [post_modified_gmt] => 2022-05-24 09:02:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 4806
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:59:08
                            [post_date_gmt] => 2022-05-24 08:59:08
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:40:29
                            [post_modified_gmt] => 2023-04-28 13:40:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 4805
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:53:12
                            [post_date_gmt] => 2022-05-24 08:53:12
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:59:42
                            [post_modified_gmt] => 2022-05-24 08:59:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 4804
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:40:15
                            [post_date_gmt] => 2022-05-24 08:40:15
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:53:51
                            [post_modified_gmt] => 2022-05-24 08:53:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 4802
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:24:23
                            [post_date_gmt] => 2022-05-24 08:24:23
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:24:23
                            [post_modified_gmt] => 2022-05-24 08:24:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 4801
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:19:21
                            [post_date_gmt] => 2022-05-24 08:19:21
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:40:03
                            [post_modified_gmt] => 2023-04-28 13:40:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 4800
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:07:39
                            [post_date_gmt] => 2022-05-24 08:07:39
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:53:27
                            [post_modified_gmt] => 2022-10-12 12:53:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 4798
                            [post_author] => 5
                            [post_date] => 2022-05-23 14:11:13
                            [post_date_gmt] => 2022-05-23 14:11:13
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-02-03 13:36:05
                            [post_modified_gmt] => 2023-02-03 13:36:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 4797
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:57
                            [post_date_gmt] => 2022-05-23 13:54:57
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:28:31
                            [post_modified_gmt] => 2022-07-13 12:28:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 4796
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:05
                            [post_date_gmt] => 2022-05-23 13:54:05
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:39:34
                            [post_modified_gmt] => 2023-04-28 13:39:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 4661
                            [post_author] => 5
                            [post_date] => 2022-04-20 08:13:06
                            [post_date_gmt] => 2022-04-20 08:13:06
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:53:17
                            [post_modified_gmt] => 2022-10-03 13:53:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 4147
                            [post_author] => 5
                            [post_date] => 2022-04-18 12:53:51
                            [post_date_gmt] => 2022-04-18 12:53:51
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:24:43
                            [post_modified_gmt] => 2022-12-15 16:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 4601
                            [post_author] => 5
                            [post_date] => 2022-04-18 10:40:48
                            [post_date_gmt] => 2022-04-18 10:40:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 10:44:46
                            [post_modified_gmt] => 2022-04-18 10:44:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4601
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 4148
                            [post_author] => 5
                            [post_date] => 2022-04-12 08:59:45
                            [post_date_gmt] => 2022-04-12 08:59:45
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:25:17
                            [post_modified_gmt] => 2023-05-01 14:25:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 4223
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:43:58
                            [post_date_gmt] => 2022-03-04 09:43:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 18:00:18
                            [post_modified_gmt] => 2022-05-31 18:00:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4223
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 4222
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:14:41
                            [post_date_gmt] => 2022-03-04 09:14:41
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:13:06
                            [post_modified_gmt] => 2022-10-12 11:13:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4222
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 4221
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:05:29
                            [post_date_gmt] => 2022-03-04 09:05:29
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:36:15
                            [post_modified_gmt] => 2022-09-26 14:36:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 4220
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:47:04
                            [post_date_gmt] => 2022-03-04 08:47:04
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:22:53
                            [post_modified_gmt] => 2023-04-28 13:22:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 4219
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:02:15
                            [post_date_gmt] => 2022-03-04 08:02:15
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:55:41
                            [post_modified_gmt] => 2023-01-04 15:55:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 4218
                            [post_author] => 5
                            [post_date] => 2022-03-03 14:17:53
                            [post_date_gmt] => 2022-03-03 14:17:53
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:10:14
                            [post_modified_gmt] => 2023-01-04 15:10:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 4217
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:59:58
                            [post_date_gmt] => 2022-03-03 13:59:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 17:56:43
                            [post_modified_gmt] => 2022-05-31 17:56:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 4216
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:45:21
                            [post_date_gmt] => 2022-03-03 13:45:21
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 17:56:00
                            [post_modified_gmt] => 2022-05-31 17:56:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 4215
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:31:56
                            [post_date_gmt] => 2022-03-03 13:31:56
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:41:55
                            [post_modified_gmt] => 2022-09-29 10:41:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 4214
                            [post_author] => 5
                            [post_date] => 2022-03-03 12:54:33
                            [post_date_gmt] => 2022-03-03 12:54:33
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:21:12
                            [post_modified_gmt] => 2023-04-28 13:21:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4214
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 4213
                            [post_author] => 5
                            [post_date] => 2022-03-03 10:54:01
                            [post_date_gmt] => 2022-03-03 10:54:01
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 15:05:32
                            [post_modified_gmt] => 2022-05-31 15:05:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4213
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 4212
                            [post_author] => 5
                            [post_date] => 2022-03-02 14:54:16
                            [post_date_gmt] => 2022-03-02 14:54:16
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:20:51
                            [post_modified_gmt] => 2023-04-28 13:20:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4212
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 4210
                            [post_author] => 5
                            [post_date] => 2022-03-02 13:14:31
                            [post_date_gmt] => 2022-03-02 13:14:31
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:03:49
                            [post_modified_gmt] => 2022-07-13 12:03:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4210
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 4209
                            [post_author] => 5
                            [post_date] => 2022-03-02 12:07:13
                            [post_date_gmt] => 2022-03-02 12:07:13
                            [post_content] => 
                            [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:16:54
                            [post_modified_gmt] => 2022-10-13 13:16:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4209
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 4205
                            [post_author] => 5
                            [post_date] => 2022-02-28 15:24:19
                            [post_date_gmt] => 2022-02-28 15:24:19
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:59:13
                            [post_modified_gmt] => 2022-10-12 12:59:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 4204
                            [post_author] => 5
                            [post_date] => 2022-02-28 14:53:11
                            [post_date_gmt] => 2022-02-28 14:53:11
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:07:32
                            [post_modified_gmt] => 2022-12-14 13:07:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 4201
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:33:22
                            [post_date_gmt] => 2022-02-28 13:33:22
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 13:13:57
                            [post_modified_gmt] => 2023-01-10 13:13:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:13:52
                            [post_modified_gmt] => 2022-10-12 11:13:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 4161
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:48:58
                            [post_date_gmt] => 2022-02-02 13:48:58
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:53:28
                            [post_modified_gmt] => 2022-12-15 09:53:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 4159
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:10:48
                            [post_date_gmt] => 2022-02-02 13:10:48
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:15:11
                            [post_modified_gmt] => 2022-10-12 11:15:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 4158
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:00:08
                            [post_date_gmt] => 2022-02-02 13:00:08
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:48:45
                            [post_modified_gmt] => 2023-01-03 12:48:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 4157
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:54:56
                            [post_date_gmt] => 2022-02-02 12:54:56
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:13:37
                            [post_modified_gmt] => 2022-04-18 13:13:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 4156
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:36:42
                            [post_date_gmt] => 2022-02-02 12:36:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:10:37
                            [post_modified_gmt] => 2023-01-04 15:10:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 4155
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:19:16
                            [post_date_gmt] => 2022-02-02 12:19:16
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:12:26
                            [post_modified_gmt] => 2022-04-18 13:12:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 4154
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:13:41
                            [post_date_gmt] => 2022-02-02 12:13:41
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-02 12:13:41
                            [post_modified_gmt] => 2022-02-02 12:13:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 4153
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:10:13
                            [post_date_gmt] => 2022-02-02 12:10:13
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:28:28
                            [post_modified_gmt] => 2022-09-29 11:28:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 4152
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:51:54
                            [post_date_gmt] => 2022-02-02 11:51:54
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:57:07
                            [post_modified_gmt] => 2022-09-26 14:57:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 4151
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:39:24
                            [post_date_gmt] => 2022-02-02 11:39:24
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:00:22
                            [post_modified_gmt] => 2022-10-12 13:00:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 4150
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:24:30
                            [post_date_gmt] => 2022-02-02 10:24:30
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:01:03
                            [post_modified_gmt] => 2022-04-18 13:01:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 4149
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:15:42
                            [post_date_gmt] => 2022-02-02 10:15:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:24:14
                            [post_modified_gmt] => 2023-05-01 14:24:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 4146
                            [post_author] => 5
                            [post_date] => 2022-02-02 07:28:42
                            [post_date_gmt] => 2022-02-02 07:28:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:18:01
                            [post_modified_gmt] => 2022-10-13 13:18:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 4141
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:31:23
                            [post_date_gmt] => 2022-01-31 14:31:23
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:40:20
                            [post_modified_gmt] => 2023-01-10 10:40:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 4140
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:22:03
                            [post_date_gmt] => 2022-01-31 14:22:03
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:54:15
                            [post_modified_gmt] => 2023-01-10 10:54:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 4139
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:18:32
                            [post_date_gmt] => 2022-01-31 14:18:32
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:58:00
                            [post_modified_gmt] => 2023-01-10 10:58:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 4138
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:09:33
                            [post_date_gmt] => 2022-01-31 14:09:33
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:59:39
                            [post_modified_gmt] => 2023-01-10 10:59:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4138
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 4137
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:53:37
                            [post_date_gmt] => 2022-01-31 13:53:37
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:02:20
                            [post_modified_gmt] => 2023-01-10 11:02:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 4136
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:42:47
                            [post_date_gmt] => 2022-01-31 13:42:47
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:01:51
                            [post_modified_gmt] => 2023-01-10 11:01:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4136
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 4135
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:25:08
                            [post_date_gmt] => 2022-01-31 13:25:08
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:59:11
                            [post_modified_gmt] => 2023-01-10 10:59:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 4134
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:56:28
                            [post_date_gmt] => 2022-01-31 12:56:28
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:58:24
                            [post_modified_gmt] => 2023-01-10 10:58:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 4133
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:22:56
                            [post_date_gmt] => 2022-01-31 12:22:56
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:56:11
                            [post_modified_gmt] => 2023-01-10 10:56:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4133
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 4131
                            [post_author] => 5
                            [post_date] => 2022-01-29 16:21:19
                            [post_date_gmt] => 2022-01-29 16:21:19
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:35:36
                            [post_modified_gmt] => 2023-04-28 13:35:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 4130
                            [post_author] => 5
                            [post_date] => 2022-01-29 15:34:50
                            [post_date_gmt] => 2022-01-29 15:34:50
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:57:20
                            [post_modified_gmt] => 2023-01-10 10:57:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 4129
                            [post_author] => 5
                            [post_date] => 2022-01-28 14:43:06
                            [post_date_gmt] => 2022-01-28 14:43:06
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:34:27
                            [post_modified_gmt] => 2023-04-28 13:34:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 4128
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:38:44
                            [post_date_gmt] => 2022-01-28 13:38:44
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:07:15
                            [post_modified_gmt] => 2023-01-10 11:07:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 4058
                            [post_author] => 5
                            [post_date] => 2022-01-04 14:25:52
                            [post_date_gmt] => 2022-01-04 14:25:52
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:47:11
                            [post_modified_gmt] => 2023-01-03 12:47:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4058
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 4054
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:45:52
                            [post_date_gmt] => 2022-01-03 11:45:52
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:45:07
                            [post_modified_gmt] => 2022-12-15 14:45:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 4051
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:01:41
                            [post_date_gmt] => 2022-01-03 11:01:41
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:38:45
                            [post_modified_gmt] => 2023-05-01 14:38:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 4050
                            [post_author] => 5
                            [post_date] => 2022-01-03 10:49:32
                            [post_date_gmt] => 2022-01-03 10:49:32
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-03 10:56:55
                            [post_modified_gmt] => 2022-01-03 10:56:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4050
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 4047
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:17:36
                            [post_date_gmt] => 2021-12-27 17:17:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:05:43
                            [post_modified_gmt] => 2023-01-04 16:05:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4047
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 4046
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:10:47
                            [post_date_gmt] => 2021-12-27 17:10:47
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:16
                            [post_modified_gmt] => 2023-01-04 15:13:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4046
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 4045
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:07:25
                            [post_date_gmt] => 2021-12-27 17:07:25
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:30:11
                            [post_modified_gmt] => 2023-04-27 11:30:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4045
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 4043
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:47:54
                            [post_date_gmt] => 2021-12-27 16:47:54
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-27 16:47:54
                            [post_modified_gmt] => 2021-12-27 16:47:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4043
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 4042
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:41:56
                            [post_date_gmt] => 2021-12-27 16:41:56
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:25:56
                            [post_modified_gmt] => 2022-09-29 12:25:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4042
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 4041
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:28:21
                            [post_date_gmt] => 2021-12-27 16:28:21
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:33:53
                            [post_modified_gmt] => 2023-03-21 11:33:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4041
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 4040
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:24:04
                            [post_date_gmt] => 2021-12-27 15:24:04
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:34:34
                            [post_modified_gmt] => 2023-03-21 11:34:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4040
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 4038
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:08:30
                            [post_date_gmt] => 2021-12-27 15:08:30
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:35:46
                            [post_modified_gmt] => 2023-04-05 12:35:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4038
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 4036
                            [post_author] => 5
                            [post_date] => 2021-12-26 17:01:45
                            [post_date_gmt] => 2021-12-26 17:01:45
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:31:29
                            [post_modified_gmt] => 2023-03-21 11:31:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4036
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 4035
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:47:36
                            [post_date_gmt] => 2021-12-26 16:47:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:28:18
                            [post_modified_gmt] => 2022-12-16 13:28:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4035
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 4032
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:32:27
                            [post_date_gmt] => 2021-12-26 16:32:27
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:37:25
                            [post_modified_gmt] => 2023-05-01 14:37:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4032
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 4029
                            [post_author] => 5
                            [post_date] => 2021-12-21 12:22:08
                            [post_date_gmt] => 2021-12-21 12:22:08
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:36:19
                            [post_modified_gmt] => 2023-04-05 12:36:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4029
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 4028
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:55:28
                            [post_date_gmt] => 2021-12-21 11:55:28
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:35:05
                            [post_modified_gmt] => 2023-04-05 12:35:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4028
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 4024
                            [post_author] => 5
                            [post_date] => 2021-12-15 15:33:17
                            [post_date_gmt] => 2021-12-15 15:33:17
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 15:33:17
                            [post_modified_gmt] => 2021-12-15 15:33:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4024
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 4022
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:49:36
                            [post_date_gmt] => 2021-12-15 14:49:36
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:43:03
                            [post_modified_gmt] => 2023-04-28 13:43:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4022
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 4021
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:31:00
                            [post_date_gmt] => 2021-12-15 14:31:00
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 13:06:46
                            [post_modified_gmt] => 2023-03-21 13:06:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 4020
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:24:47
                            [post_date_gmt] => 2021-12-15 14:24:47
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:47
                            [post_modified_gmt] => 2023-01-04 15:13:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 4017
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:22:49
                            [post_date_gmt] => 2021-12-15 13:22:49
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 13:22:49
                            [post_modified_gmt] => 2021-12-15 13:22:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4017
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 4016
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:20:07
                            [post_date_gmt] => 2021-12-15 13:20:07
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:54:29
                            [post_modified_gmt] => 2022-09-29 10:54:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4016
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 4014
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:33:09
                            [post_date_gmt] => 2021-12-15 12:33:09
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:42:36
                            [post_modified_gmt] => 2023-04-28 13:42:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4014
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 4013
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:16:20
                            [post_date_gmt] => 2021-12-15 12:16:20
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-31 09:12:31
                            [post_modified_gmt] => 2023-03-31 09:12:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4013
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 4011
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:21:54
                            [post_date_gmt] => 2021-12-14 15:21:54
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:25:12
                            [post_modified_gmt] => 2022-07-13 09:25:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4011
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 4009
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:10:51
                            [post_date_gmt] => 2021-12-14 15:10:51
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:42:14
                            [post_modified_gmt] => 2023-04-28 13:42:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4009
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 4007
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:51:32
                            [post_date_gmt] => 2021-12-14 08:51:32
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-14 08:51:44
                            [post_modified_gmt] => 2021-12-14 08:51:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4007
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 4006
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:16:01
                            [post_date_gmt] => 2021-12-14 08:16:01
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 10:44:31
                            [post_modified_gmt] => 2023-04-05 10:44:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4006
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 4004
                            [post_author] => 5
                            [post_date] => 2021-12-14 07:57:41
                            [post_date_gmt] => 2021-12-14 07:57:41
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:04:14
                            [post_modified_gmt] => 2023-03-30 14:04:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 4003
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:36:53
                            [post_date_gmt] => 2021-12-13 18:36:53
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 14:03:19
                            [post_modified_gmt] => 2022-12-14 14:03:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4003
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 4002
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:28:05
                            [post_date_gmt] => 2021-12-13 18:28:05
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:57:35
                            [post_modified_gmt] => 2022-12-15 14:57:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4002
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 4001
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:55:46
                            [post_date_gmt] => 2021-12-13 14:55:46
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-31 09:11:58
                            [post_modified_gmt] => 2023-03-31 09:11:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4001
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 3997
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:24:49
                            [post_date_gmt] => 2021-12-13 14:24:49
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 07:48:18
                            [post_modified_gmt] => 2023-05-05 07:48:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3997
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 3869
                            [post_author] => 5
                            [post_date] => 2021-11-19 12:55:06
                            [post_date_gmt] => 2021-11-19 12:55:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:40:05
                            [post_modified_gmt] => 2023-05-04 11:40:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 3886
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:36:37
                            [post_date_gmt] => 2021-11-18 16:36:37
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:00:13
                            [post_modified_gmt] => 2022-12-15 15:00:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 3884
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:17:51
                            [post_date_gmt] => 2021-11-18 16:17:51
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:31:52
                            [post_modified_gmt] => 2023-05-01 14:31:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3884
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 3883
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:10:24
                            [post_date_gmt] => 2021-11-18 16:10:24
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:53:31
                            [post_modified_gmt] => 2023-01-03 12:53:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3883
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 3882
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:01:06
                            [post_date_gmt] => 2021-11-18 16:01:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 08:10:55
                            [post_modified_gmt] => 2023-05-05 08:10:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3882
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 3881
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:52:45
                            [post_date_gmt] => 2021-11-18 15:52:45
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:15:40
                            [post_modified_gmt] => 2023-01-04 15:15:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3881
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 3880
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:50:26
                            [post_date_gmt] => 2021-11-18 15:50:26
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 15:50:26
                            [post_modified_gmt] => 2021-11-18 15:50:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3880
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 3878
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:08:19
                            [post_date_gmt] => 2021-11-18 15:08:19
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 15:08:19
                            [post_modified_gmt] => 2021-11-18 15:08:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3878
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 3877
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:05:16
                            [post_date_gmt] => 2021-11-18 15:05:16
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:45:57
                            [post_modified_gmt] => 2022-09-29 11:45:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3877
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 3876
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:51:40
                            [post_date_gmt] => 2021-11-18 14:51:40
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:31:10
                            [post_modified_gmt] => 2023-05-01 14:31:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3876
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 3875
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:43:39
                            [post_date_gmt] => 2021-11-18 14:43:39
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:30:10
                            [post_modified_gmt] => 2023-05-01 14:30:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3875
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 3874
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:29:06
                            [post_date_gmt] => 2021-11-18 14:29:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:29:46
                            [post_modified_gmt] => 2023-05-01 14:29:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3874
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 3873
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:05:12
                            [post_date_gmt] => 2021-11-18 14:05:12
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:38:53
                            [post_modified_gmt] => 2023-05-04 11:38:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 3870
                            [post_author] => 5
                            [post_date] => 2021-11-18 12:58:35
                            [post_date_gmt] => 2021-11-18 12:58:35
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:37:06
                            [post_modified_gmt] => 2023-05-04 11:37:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 3863
                            [post_author] => 5
                            [post_date] => 2021-11-05 14:19:38
                            [post_date_gmt] => 2021-11-05 14:19:38
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:00:47
                            [post_modified_gmt] => 2022-12-15 15:00:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3863
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 3861
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:59:54
                            [post_date_gmt] => 2021-11-05 13:59:54
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:24:33
                            [post_modified_gmt] => 2022-10-12 11:24:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3861
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 3860
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:51:48
                            [post_date_gmt] => 2021-11-05 13:51:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 07:16:48
                            [post_modified_gmt] => 2022-04-18 07:16:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 3859
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:44:47
                            [post_date_gmt] => 2021-11-05 13:44:47
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:12:49
                            [post_modified_gmt] => 2023-01-04 16:12:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3859
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 3858
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:39:37
                            [post_date_gmt] => 2021-11-05 13:39:37
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:16:05
                            [post_modified_gmt] => 2023-01-04 15:16:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3858
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 3857
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:37:12
                            [post_date_gmt] => 2021-11-05 13:37:12
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 07:41:41
                            [post_modified_gmt] => 2022-04-18 07:41:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3857
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 3856
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:12:38
                            [post_date_gmt] => 2021-11-05 13:12:38
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:54:20
                            [post_modified_gmt] => 2022-09-26 14:54:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3856
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 3855
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:10:25
                            [post_date_gmt] => 2021-11-05 13:10:25
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 08:19:07
                            [post_modified_gmt] => 2023-04-27 08:19:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3855
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 3854
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:03:41
                            [post_date_gmt] => 2021-11-05 13:03:41
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 11:50:20
                            [post_modified_gmt] => 2023-04-05 11:50:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3854
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 3852
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:43:57
                            [post_date_gmt] => 2021-11-05 12:43:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 08:33:20
                            [post_modified_gmt] => 2022-04-18 08:33:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3852
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 3851
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:41:54
                            [post_date_gmt] => 2021-11-05 12:41:54
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:14:19
                            [post_modified_gmt] => 2022-10-12 13:14:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3851
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 3849
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:30:09
                            [post_date_gmt] => 2021-11-05 12:30:09
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 08:52:12
                            [post_modified_gmt] => 2022-04-18 08:52:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3849
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 3848
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:27:44
                            [post_date_gmt] => 2021-11-05 12:27:44
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 08:13:29
                            [post_modified_gmt] => 2023-04-27 08:13:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3848
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 3847
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:25:40
                            [post_date_gmt] => 2021-11-05 12:25:40
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:00:30
                            [post_modified_gmt] => 2023-05-04 11:00:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3847
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 3846
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:14:17
                            [post_date_gmt] => 2021-11-05 12:14:17
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:02:17
                            [post_modified_gmt] => 2022-07-13 13:02:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3846
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 3819
                            [post_author] => 6
                            [post_date] => 2021-09-15 12:17:55
                            [post_date_gmt] => 2021-09-15 12:17:55
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 07:48:46
                            [post_modified_gmt] => 2023-05-05 07:48:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3819
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 3812
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:44:57
                            [post_date_gmt] => 2021-09-10 12:44:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:53:37
                            [post_modified_gmt] => 2022-10-03 13:53:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 3810
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:21:33
                            [post_date_gmt] => 2021-09-10 12:21:33
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:36:42
                            [post_modified_gmt] => 2023-05-01 14:36:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 3809
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:11:12
                            [post_date_gmt] => 2021-09-10 12:11:12
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:54:22
                            [post_modified_gmt] => 2022-10-03 13:54:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 3808
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:59:11
                            [post_date_gmt] => 2021-09-10 11:59:11
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 08:32:00
                            [post_modified_gmt] => 2022-12-16 08:32:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 3807
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:55:25
                            [post_date_gmt] => 2021-09-10 11:55:25
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-17 10:11:39
                            [post_modified_gmt] => 2023-05-17 10:11:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 3806
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:47:18
                            [post_date_gmt] => 2021-09-10 11:47:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:55:26
                            [post_modified_gmt] => 2022-10-03 13:55:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 13:02:35
                            [post_modified_gmt] => 2023-01-03 13:02:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 3804
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:20:59
                            [post_date_gmt] => 2021-09-10 11:20:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 12:59:30
                            [post_modified_gmt] => 2023-03-21 12:59:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 3803
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:54:42
                            [post_date_gmt] => 2021-09-10 10:54:42
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:57:32
                            [post_modified_gmt] => 2022-10-03 13:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 3802
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:45:57
                            [post_date_gmt] => 2021-09-10 10:45:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:58:08
                            [post_modified_gmt] => 2022-10-03 13:58:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 3801
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:36:30
                            [post_date_gmt] => 2021-09-10 10:36:30
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:47:05
                            [post_modified_gmt] => 2022-12-14 15:47:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 3800
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:25:59
                            [post_date_gmt] => 2021-09-10 10:25:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:46:27
                            [post_modified_gmt] => 2023-05-04 11:46:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 3799
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:07:18
                            [post_date_gmt] => 2021-09-10 10:07:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:45:40
                            [post_modified_gmt] => 2022-12-16 12:45:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 3798
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:02:07
                            [post_date_gmt] => 2021-09-10 10:02:07
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:59:19
                            [post_modified_gmt] => 2022-10-03 13:59:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 3797
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:54:44
                            [post_date_gmt] => 2021-09-10 09:54:44
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:59:36
                            [post_modified_gmt] => 2022-10-03 13:59:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 3796
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:03:43
                            [post_date_gmt] => 2021-09-10 09:03:43
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 15:00:19
                            [post_modified_gmt] => 2022-11-09 15:00:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [221] => WP_Post Object
                        (
                            [ID] => 3792
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:23:13
                            [post_date_gmt] => 2021-09-09 14:23:13
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:24:00
                            [post_modified_gmt] => 2022-12-14 13:24:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [222] => WP_Post Object
                        (
                            [ID] => 3791
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:18:44
                            [post_date_gmt] => 2021-09-09 14:18:44
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 13:14:39
                            [post_modified_gmt] => 2023-01-03 13:14:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [223] => WP_Post Object
                        (
                            [ID] => 3789
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:07:30
                            [post_date_gmt] => 2021-09-09 14:07:30
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:32:36
                            [post_modified_gmt] => 2022-09-29 12:32:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3789
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [224] => WP_Post Object
                        (
                            [ID] => 3788
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:00:40
                            [post_date_gmt] => 2021-09-09 14:00:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-04 09:02:12
                            [post_modified_gmt] => 2021-11-04 09:02:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3788
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [225] => WP_Post Object
                        (
                            [ID] => 3786
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:20:21
                            [post_date_gmt] => 2021-09-09 13:20:21
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:28:45
                            [post_modified_gmt] => 2023-05-02 13:28:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3786
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [226] => WP_Post Object
                        (
                            [ID] => 3784
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:03:52
                            [post_date_gmt] => 2021-09-09 13:03:52
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:52:03
                            [post_modified_gmt] => 2022-12-16 12:52:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3784
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [227] => WP_Post Object
                        (
                            [ID] => 3783
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:41:47
                            [post_date_gmt] => 2021-09-09 12:41:47
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:33:19
                            [post_modified_gmt] => 2022-12-16 13:33:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3783
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [228] => WP_Post Object
                        (
                            [ID] => 3782
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:36:36
                            [post_date_gmt] => 2021-09-09 12:36:36
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:26:23
                            [post_modified_gmt] => 2023-05-02 13:26:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [229] => WP_Post Object
                        (
                            [ID] => 3781
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:29:54
                            [post_date_gmt] => 2021-09-09 12:29:54
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:06:09
                            [post_modified_gmt] => 2022-12-15 15:06:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3781
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [230] => WP_Post Object
                        (
                            [ID] => 3778
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:52:53
                            [post_date_gmt] => 2021-09-09 11:52:53
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:25:45
                            [post_modified_gmt] => 2023-05-02 13:25:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3778
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [231] => WP_Post Object
                        (
                            [ID] => 3765
                            [post_author] => 5
                            [post_date] => 2021-09-01 14:09:03
                            [post_date_gmt] => 2021-09-01 14:09:03
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 08:33:18
                            [post_modified_gmt] => 2022-12-16 08:33:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3765
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [232] => WP_Post Object
                        (
                            [ID] => 3764
                            [post_author] => 5
                            [post_date] => 2021-09-01 12:17:32
                            [post_date_gmt] => 2021-09-01 12:17:32
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:59:16
                            [post_modified_gmt] => 2022-09-26 14:59:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3764
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [233] => WP_Post Object
                        (
                            [ID] => 3758
                            [post_author] => 5
                            [post_date] => 2021-08-26 12:04:03
                            [post_date_gmt] => 2021-08-26 12:04:03
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:09:10
                            [post_modified_gmt] => 2023-05-02 13:09:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3758
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [234] => WP_Post Object
                        (
                            [ID] => 3741
                            [post_author] => 5
                            [post_date] => 2021-08-24 09:13:39
                            [post_date_gmt] => 2021-08-24 09:13:39
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:25:32
                            [post_modified_gmt] => 2022-09-26 14:25:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [235] => WP_Post Object
                        (
                            [ID] => 3696
                            [post_author] => 5
                            [post_date] => 2021-08-19 14:23:22
                            [post_date_gmt] => 2021-08-19 14:23:22
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 07:52:58
                            [post_modified_gmt] => 2022-12-15 07:52:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [236] => WP_Post Object
                        (
                            [ID] => 3495
                            [post_author] => 5
                            [post_date] => 2021-08-10 13:06:45
                            [post_date_gmt] => 2021-08-10 13:06:45
                            [post_content] => 
                            [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dod-moderna-covid-19-vaccine-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:00:22
                            [post_modified_gmt] => 2022-12-15 09:00:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3495
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [237] => WP_Post Object
                        (
                            [ID] => 3493
                            [post_author] => 5
                            [post_date] => 2021-08-10 11:15:39
                            [post_date_gmt] => 2021-08-10 11:15:39
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 14:19:31
                            [post_modified_gmt] => 2023-01-10 14:19:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [238] => WP_Post Object
                        (
                            [ID] => 3436
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:48:49
                            [post_date_gmt] => 2021-07-01 03:48:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:25:22
                            [post_modified_gmt] => 2022-09-29 11:25:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [239] => WP_Post Object
                        (
                            [ID] => 3434
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:44:18
                            [post_date_gmt] => 2021-07-01 03:44:18
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:34:30
                            [post_modified_gmt] => 2022-10-12 13:34:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [240] => WP_Post Object
                        (
                            [ID] => 3433
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:41:21
                            [post_date_gmt] => 2021-07-01 03:41:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 14:50:06
                            [post_modified_gmt] => 2022-12-14 14:50:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [241] => WP_Post Object
                        (
                            [ID] => 3431
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:38:49
                            [post_date_gmt] => 2021-07-01 03:38:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 09:41:10
                            [post_modified_gmt] => 2022-04-18 09:41:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [242] => WP_Post Object
                        (
                            [ID] => 3430
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:27:51
                            [post_date_gmt] => 2021-07-01 03:27:51
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 12:42:32
                            [post_modified_gmt] => 2023-04-27 12:42:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [243] => WP_Post Object
                        (
                            [ID] => 3428
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:24:00
                            [post_date_gmt] => 2021-07-01 03:24:00
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:52:47
                            [post_modified_gmt] => 2022-09-26 14:52:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [244] => WP_Post Object
                        (
                            [ID] => 3427
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:22:23
                            [post_date_gmt] => 2021-07-01 03:22:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 12:42:09
                            [post_modified_gmt] => 2023-04-27 12:42:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [245] => WP_Post Object
                        (
                            [ID] => 3426
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:06:23
                            [post_date_gmt] => 2021-07-01 03:06:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:25:19
                            [post_modified_gmt] => 2023-01-04 15:25:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [246] => WP_Post Object
                        (
                            [ID] => 3424
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:03:57
                            [post_date_gmt] => 2021-07-01 03:03:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-29 08:13:59
                            [post_modified_gmt] => 2023-03-29 08:13:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [247] => WP_Post Object
                        (
                            [ID] => 3422
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:58:21
                            [post_date_gmt] => 2021-07-01 02:58:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:14:53
                            [post_modified_gmt] => 2022-11-10 12:14:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [248] => WP_Post Object
                        (
                            [ID] => 3421
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:56:30
                            [post_date_gmt] => 2021-07-01 02:56:30
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 07:58:57
                            [post_modified_gmt] => 2023-05-05 07:58:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3421
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [249] => WP_Post Object
                        (
                            [ID] => 3420
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:52:05
                            [post_date_gmt] => 2021-07-01 02:52:05
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 12:41:15
                            [post_modified_gmt] => 2023-04-27 12:41:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3420
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [250] => WP_Post Object
                        (
                            [ID] => 3372
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:06:19
                            [post_date_gmt] => 2021-06-30 15:06:19
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:46:34
                            [post_modified_gmt] => 2022-10-12 13:46:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3372
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [251] => WP_Post Object
                        (
                            [ID] => 3370
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:01:06
                            [post_date_gmt] => 2021-06-30 15:01:06
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:46:41
                            [post_modified_gmt] => 2022-10-12 13:46:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3370
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [252] => WP_Post Object
                        (
                            [ID] => 3368
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:58:39
                            [post_date_gmt] => 2021-06-30 14:58:39
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:43:13
                            [post_modified_gmt] => 2022-12-16 13:43:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3368
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [253] => WP_Post Object
                        (
                            [ID] => 3366
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:53:53
                            [post_date_gmt] => 2021-06-30 14:53:53
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:54:55
                            [post_modified_gmt] => 2023-04-27 11:54:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3366
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [254] => WP_Post Object
                        (
                            [ID] => 3364
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:47:34
                            [post_date_gmt] => 2021-06-30 14:47:34
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:44:44
                            [post_modified_gmt] => 2022-12-16 13:44:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3364
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [255] => WP_Post Object
                        (
                            [ID] => 3361
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:30:51
                            [post_date_gmt] => 2021-06-30 14:30:51
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-06 11:29:48
                            [post_modified_gmt] => 2023-04-06 11:29:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3361
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [256] => WP_Post Object
                        (
                            [ID] => 3360
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:28:40
                            [post_date_gmt] => 2021-06-30 14:28:40
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:16:14
                            [post_modified_gmt] => 2022-11-10 12:16:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3360
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [257] => WP_Post Object
                        (
                            [ID] => 3356
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:53:23
                            [post_date_gmt] => 2021-06-30 13:53:23
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:24:04
                            [post_modified_gmt] => 2023-01-03 15:24:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [258] => WP_Post Object
                        (
                            [ID] => 3354
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:29:21
                            [post_date_gmt] => 2021-06-30 13:29:21
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:52:50
                            [post_modified_gmt] => 2023-04-27 11:52:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3354
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [259] => WP_Post Object
                        (
                            [ID] => 3352
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:24:49
                            [post_date_gmt] => 2021-06-30 13:24:49
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:47:30
                            [post_modified_gmt] => 2022-10-12 13:47:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3352
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [260] => WP_Post Object
                        (
                            [ID] => 3221
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:23:49
                            [post_date_gmt] => 2021-06-28 12:23:49
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:47:45
                            [post_modified_gmt] => 2022-09-27 09:47:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [261] => WP_Post Object
                        (
                            [ID] => 3220
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:22:09
                            [post_date_gmt] => 2021-06-28 12:22:09
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:22:07
                            [post_modified_gmt] => 2022-10-12 12:22:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [262] => WP_Post Object
                        (
                            [ID] => 3219
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:19:29
                            [post_date_gmt] => 2021-06-28 12:19:29
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:28:41
                            [post_modified_gmt] => 2022-09-29 12:28:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [263] => WP_Post Object
                        (
                            [ID] => 3218
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:16:20
                            [post_date_gmt] => 2021-06-28 12:16:20
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 14:31:28
                            [post_modified_gmt] => 2022-10-12 14:31:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [264] => WP_Post Object
                        (
                            [ID] => 3217
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:14:37
                            [post_date_gmt] => 2021-06-28 12:14:37
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:11:47
                            [post_modified_gmt] => 2022-12-15 09:11:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [265] => WP_Post Object
                        (
                            [ID] => 3215
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:07:55
                            [post_date_gmt] => 2021-06-28 12:07:55
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 11:33:05
                            [post_modified_gmt] => 2022-07-13 11:33:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [266] => WP_Post Object
                        (
                            [ID] => 3127
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:08:41
                            [post_date_gmt] => 2021-06-03 15:08:41
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:47:06
                            [post_modified_gmt] => 2022-09-27 09:47:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [267] => WP_Post Object
                        (
                            [ID] => 3126
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:05:40
                            [post_date_gmt] => 2021-06-03 15:05:40
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:38:12
                            [post_modified_gmt] => 2023-01-04 15:38:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3126
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [268] => WP_Post Object
                        (
                            [ID] => 3125
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:03:17
                            [post_date_gmt] => 2021-06-03 15:03:17
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:22:26
                            [post_modified_gmt] => 2022-10-12 12:22:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [269] => WP_Post Object
                        (
                            [ID] => 3124
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:01:23
                            [post_date_gmt] => 2021-06-03 15:01:23
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-23 09:52:56
                            [post_modified_gmt] => 2021-08-23 09:52:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [270] => WP_Post Object
                        (
                            [ID] => 3123
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:51:22
                            [post_date_gmt] => 2021-06-03 14:51:22
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:02:53
                            [post_modified_gmt] => 2022-09-29 11:02:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [271] => WP_Post Object
                        (
                            [ID] => 3122
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:45:44
                            [post_date_gmt] => 2021-06-03 14:45:44
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 14:32:30
                            [post_modified_gmt] => 2022-10-12 14:32:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [272] => WP_Post Object
                        (
                            [ID] => 3121
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:26:32
                            [post_date_gmt] => 2021-06-03 14:26:32
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:13:08
                            [post_modified_gmt] => 2022-12-15 09:13:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [273] => WP_Post Object
                        (
                            [ID] => 3120
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:24:03
                            [post_date_gmt] => 2021-06-03 14:24:03
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:39:28
                            [post_modified_gmt] => 2022-12-15 15:39:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [274] => WP_Post Object
                        (
                            [ID] => 3119
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:21:50
                            [post_date_gmt] => 2021-06-03 14:21:50
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 11:05:12
                            [post_modified_gmt] => 2022-07-13 11:05:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [275] => WP_Post Object
                        (
                            [ID] => 2956
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:56:15
                            [post_date_gmt] => 2021-05-28 18:56:15
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 15:38:41
                            [post_modified_gmt] => 2022-10-12 15:38:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2956
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [276] => WP_Post Object
                        (
                            [ID] => 2961
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:55:47
                            [post_date_gmt] => 2021-05-28 18:55:47
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:36:28
                            [post_modified_gmt] => 2023-01-04 16:36:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2961
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [277] => WP_Post Object
                        (
                            [ID] => 2965
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:55:12
                            [post_date_gmt] => 2021-05-28 18:55:12
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:42:06
                            [post_modified_gmt] => 2022-12-15 15:42:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2965
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [278] => WP_Post Object
                        (
                            [ID] => 2947
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:54:17
                            [post_date_gmt] => 2021-05-28 18:54:17
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:51:47
                            [post_modified_gmt] => 2022-12-14 15:51:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2947
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [279] => WP_Post Object
                        (
                            [ID] => 2960
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:53:36
                            [post_date_gmt] => 2021-05-28 18:53:36
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:39:20
                            [post_modified_gmt] => 2023-01-04 15:39:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2960
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [280] => WP_Post Object
                        (
                            [ID] => 2964
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:53:11
                            [post_date_gmt] => 2021-05-28 18:53:11
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:44:06
                            [post_modified_gmt] => 2022-12-15 16:44:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2964
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [281] => WP_Post Object
                        (
                            [ID] => 2958
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:52:54
                            [post_date_gmt] => 2021-05-28 18:52:54
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-03 10:13:48
                            [post_modified_gmt] => 2021-12-03 10:13:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2958
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [282] => WP_Post Object
                        (
                            [ID] => 2949
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:52:06
                            [post_date_gmt] => 2021-05-28 18:52:06
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:37:27
                            [post_modified_gmt] => 2022-12-15 09:37:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2949
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [283] => WP_Post Object
                        (
                            [ID] => 2957
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:51:39
                            [post_date_gmt] => 2021-05-28 18:51:39
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 09:29:34
                            [post_modified_gmt] => 2022-09-29 09:29:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2957
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [284] => WP_Post Object
                        (
                            [ID] => 2962
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:50:18
                            [post_date_gmt] => 2021-05-28 18:50:18
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:39:44
                            [post_modified_gmt] => 2023-01-03 15:39:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [285] => WP_Post Object
                        (
                            [ID] => 2945
                            [post_author] => 6
                            [post_date] => 2021-05-28 14:03:27
                            [post_date_gmt] => 2021-05-28 14:03:27
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:09:43
                            [post_modified_gmt] => 2022-07-13 09:09:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2945
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [286] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 13:01:48
                            [post_modified_gmt] => 2023-04-27 13:01:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [287] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:41:07
                            [post_modified_gmt] => 2023-03-30 14:41:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [288] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:27:11
                            [post_modified_gmt] => 2023-03-30 14:27:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [289] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-28 14:17:46
                            [post_modified_gmt] => 2023-03-28 14:17:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [290] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-29 08:29:42
                            [post_modified_gmt] => 2023-03-29 08:29:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [291] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:26:43
                            [post_modified_gmt] => 2023-03-30 14:26:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [292] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-17 10:10:41
                            [post_modified_gmt] => 2023-05-17 10:10:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [293] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 13:16:30
                            [post_modified_gmt] => 2023-01-10 13:16:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [294] => WP_Post Object
                        (
                            [ID] => 2824
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:39:49
                            [post_date_gmt] => 2021-04-16 16:39:49
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:32:00
                            [post_modified_gmt] => 2022-09-29 12:32:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [295] => WP_Post Object
                        (
                            [ID] => 2822
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:09:31
                            [post_date_gmt] => 2021-04-16 16:09:31
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:49:41
                            [post_modified_gmt] => 2022-12-15 15:49:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [296] => WP_Post Object
                        (
                            [ID] => 2820
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:44:14
                            [post_date_gmt] => 2021-04-16 12:44:14
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:24:43
                            [post_modified_gmt] => 2023-05-02 13:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [297] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:41:14
                            [post_modified_gmt] => 2023-01-03 15:41:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [298] => WP_Post Object
                        (
                            [ID] => 2749
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:10:16
                            [post_date_gmt] => 2021-03-30 15:10:16
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:51:19
                            [post_modified_gmt] => 2023-04-27 11:51:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [299] => WP_Post Object
                        (
                            [ID] => 2748
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:05:46
                            [post_date_gmt] => 2021-03-30 15:05:46
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2748
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:41:58
                            [post_modified_gmt] => 2023-01-04 15:41:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [300] => WP_Post Object
                        (
                            [ID] => 2743
                            [post_author] => 5
                            [post_date] => 2021-03-24 15:11:40
                            [post_date_gmt] => 2021-03-24 15:11:40
                            [post_content] => 
                            [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:36:08
                            [post_modified_gmt] => 2022-09-29 12:36:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [301] => WP_Post Object
                        (
                            [ID] => 2742
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:37:07
                            [post_date_gmt] => 2021-03-24 13:37:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-12 12:28:13
                            [post_modified_gmt] => 2021-08-12 12:28:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [302] => WP_Post Object
                        (
                            [ID] => 2741
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:32:55
                            [post_date_gmt] => 2021-03-24 13:32:55
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 14:20:32
                            [post_modified_gmt] => 2022-12-19 14:20:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [303] => WP_Post Object
                        (
                            [ID] => 2739
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:12:14
                            [post_date_gmt] => 2021-03-24 13:12:14
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:29:33
                            [post_modified_gmt] => 2023-05-02 13:29:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [304] => WP_Post Object
                        (
                            [ID] => 2737
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:00:46
                            [post_date_gmt] => 2021-03-24 13:00:46
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:01:31
                            [post_modified_gmt] => 2022-12-15 16:01:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [305] => WP_Post Object
                        (
                            [ID] => 2736
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:15:15
                            [post_date_gmt] => 2021-03-23 18:15:15
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:18:17
                            [post_modified_gmt] => 2022-11-10 12:18:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [306] => WP_Post Object
                        (
                            [ID] => 2734
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:01:22
                            [post_date_gmt] => 2021-03-23 18:01:22
                            [post_content] => 
                            [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-31 10:53:46
                            [post_modified_gmt] => 2022-08-31 10:53:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [307] => WP_Post Object
                        (
                            [ID] => 2543
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:15:58
                            [post_date_gmt] => 2021-03-12 18:15:58
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:52:25
                            [post_modified_gmt] => 2022-12-14 15:52:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [308] => WP_Post Object
                        (
                            [ID] => 2540
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:12:48
                            [post_date_gmt] => 2021-03-12 18:12:48
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:38:53
                            [post_modified_gmt] => 2022-12-15 09:38:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [309] => WP_Post Object
                        (
                            [ID] => 2541
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:11:14
                            [post_date_gmt] => 2021-03-12 18:11:14
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:13:39
                            [post_modified_gmt] => 2022-12-15 16:13:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [310] => WP_Post Object
                        (
                            [ID] => 2542
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:21:07
                            [post_date_gmt] => 2021-03-12 14:21:07
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-05 10:17:48
                            [post_modified_gmt] => 2022-01-05 10:17:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [311] => WP_Post Object
                        (
                            [ID] => 2544
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:16:06
                            [post_date_gmt] => 2021-03-12 14:16:06
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:18:46
                            [post_modified_gmt] => 2022-11-10 12:18:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [312] => WP_Post Object
                        (
                            [ID] => 2545
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:14:38
                            [post_date_gmt] => 2021-03-12 14:14:38
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:25:10
                            [post_modified_gmt] => 2022-10-12 12:25:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [313] => WP_Post Object
                        (
                            [ID] => 2547
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:58:55
                            [post_date_gmt] => 2021-03-12 13:58:55
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 12:56:48
                            [post_modified_gmt] => 2023-04-27 12:56:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [314] => WP_Post Object
                        (
                            [ID] => 2549
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:50:41
                            [post_date_gmt] => 2021-03-12 13:50:41
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:10:07
                            [post_modified_gmt] => 2022-12-16 13:10:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [315] => WP_Post Object
                        (
                            [ID] => 2553
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:47:42
                            [post_date_gmt] => 2021-03-12 13:47:42
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:46:21
                            [post_modified_gmt] => 2023-01-03 15:46:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [316] => WP_Post Object
                        (
                            [ID] => 2457
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:57
                            [post_date_gmt] => 2021-02-25 15:25:57
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 13:59:51
                            [post_modified_gmt] => 2023-05-05 13:59:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [317] => WP_Post Object
                        (
                            [ID] => 2461
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:35
                            [post_date_gmt] => 2021-02-25 15:23:35
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 14:25:30
                            [post_modified_gmt] => 2022-12-19 14:25:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [318] => WP_Post Object
                        (
                            [ID] => 2462
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:19
                            [post_date_gmt] => 2021-02-25 15:23:19
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:19:06
                            [post_modified_gmt] => 2022-11-10 12:19:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [319] => WP_Post Object
                        (
                            [ID] => 2463
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:22:52
                            [post_date_gmt] => 2021-02-25 15:22:52
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:17:42
                            [post_modified_gmt] => 2022-12-15 16:17:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [320] => WP_Post Object
                        (
                            [ID] => 2464
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:51
                            [post_date_gmt] => 2021-02-25 15:21:51
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 09:50:43
                            [post_modified_gmt] => 2022-10-13 09:50:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [321] => WP_Post Object
                        (
                            [ID] => 2465
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:32
                            [post_date_gmt] => 2021-02-25 15:21:32
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:37:58
                            [post_modified_gmt] => 2022-09-29 12:37:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [322] => WP_Post Object
                        (
                            [ID] => 2466
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:40
                            [post_date_gmt] => 2021-02-25 15:20:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:30:24
                            [post_modified_gmt] => 2023-05-02 13:30:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [323] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:25:37
                            [post_modified_gmt] => 2022-10-12 12:25:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [324] => WP_Post Object
                        (
                            [ID] => 2470
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:24:13
                            [post_date_gmt] => 2021-01-25 13:24:13
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-28 13:54:22
                            [post_modified_gmt] => 2022-03-28 13:54:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [325] => WP_Post Object
                        (
                            [ID] => 2473
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:21:58
                            [post_date_gmt] => 2021-01-25 13:21:58
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:18:34
                            [post_modified_gmt] => 2022-12-15 16:18:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [326] => WP_Post Object
                        (
                            [ID] => 2474
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:19:34
                            [post_date_gmt] => 2021-01-25 13:19:34
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-04 12:54:44
                            [post_modified_gmt] => 2022-01-04 12:54:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [327] => WP_Post Object
                        (
                            [ID] => 2475
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:53
                            [post_date_gmt] => 2021-01-25 13:18:53
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:38:17
                            [post_modified_gmt] => 2022-12-14 15:38:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [328] => WP_Post Object
                        (
                            [ID] => 2476
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:09
                            [post_date_gmt] => 2021-01-25 13:18:09
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 07:50:47
                            [post_modified_gmt] => 2023-05-05 07:50:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [329] => WP_Post Object
                        (
                            [ID] => 2477
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:16:23
                            [post_date_gmt] => 2021-01-25 13:16:23
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:26:04
                            [post_modified_gmt] => 2022-10-12 12:26:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [330] => WP_Post Object
                        (
                            [ID] => 2479
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:12:32
                            [post_date_gmt] => 2021-01-25 13:12:32
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:51:44
                            [post_modified_gmt] => 2023-04-28 13:51:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [331] => WP_Post Object
                        (
                            [ID] => 2481
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:08
                            [post_date_gmt] => 2021-01-25 13:11:08
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:10:44
                            [post_modified_gmt] => 2022-12-16 13:10:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [332] => WP_Post Object
                        (
                            [ID] => 2482
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:09:37
                            [post_date_gmt] => 2021-01-25 13:09:37
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:39:54
                            [post_modified_gmt] => 2023-01-04 16:39:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [333] => WP_Post Object
                        (
                            [ID] => 2471
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:02
                            [post_date_gmt] => 2021-01-25 13:08:02
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:39:40
                            [post_modified_gmt] => 2022-12-15 09:39:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [334] => WP_Post Object
                        (
                            [ID] => 2452
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:41:19
                            [post_date_gmt] => 2021-01-19 11:41:19
                            [post_content] => 
                            [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 10:45:07
                            [post_modified_gmt] => 2022-12-16 10:45:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [335] => WP_Post Object
                        (
                            [ID] => 2450
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:04:23
                            [post_date_gmt] => 2021-01-19 11:04:23
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:35:11
                            [post_modified_gmt] => 2022-09-29 12:35:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [336] => WP_Post Object
                        (
                            [ID] => 2449
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:47:27
                            [post_date_gmt] => 2021-01-19 10:47:27
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:22:44
                            [post_modified_gmt] => 2022-12-15 16:22:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [337] => WP_Post Object
                        (
                            [ID] => 2448
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:24:45
                            [post_date_gmt] => 2021-01-19 10:24:45
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 09:59:16
                            [post_modified_gmt] => 2022-10-13 09:59:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [338] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:26:34
                            [post_modified_gmt] => 2022-10-12 12:26:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [339] => WP_Post Object
                        (
                            [ID] => 2443
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:14:03
                            [post_date_gmt] => 2021-01-19 09:14:03
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 10:09:22
                            [post_modified_gmt] => 2022-10-13 10:09:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [340] => WP_Post Object
                        (
                            [ID] => 2442
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:56:32
                            [post_date_gmt] => 2021-01-19 06:56:32
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-02 13:19:25
                            [post_modified_gmt] => 2023-05-02 13:19:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [341] => WP_Post Object
                        (
                            [ID] => 2441
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:48:04
                            [post_date_gmt] => 2021-01-19 06:48:04
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:40:30
                            [post_modified_gmt] => 2022-09-29 12:40:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [342] => WP_Post Object
                        (
                            [ID] => 2426
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:08
                            [post_date_gmt] => 2020-12-14 15:02:08
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:59:51
                            [post_modified_gmt] => 2023-05-04 11:59:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [343] => WP_Post Object
                        (
                            [ID] => 2424
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:01:40
                            [post_date_gmt] => 2020-12-14 15:01:40
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:56:17
                            [post_modified_gmt] => 2023-05-04 11:56:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [344] => WP_Post Object
                        (
                            [ID] => 3910
                            [post_author] => 5
                            [post_date] => 2022-12-15 14:44:16
                            [post_date_gmt] => 2022-12-15 14:44:16
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-21 15:31:00
                            [post_modified_gmt] => 2023-04-21 15:31:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3910
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [345] => WP_Post Object
                        (
                            [ID] => 3909
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:29:28
                            [post_date_gmt] => 2021-11-22 13:29:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:06
                            [post_modified_gmt] => 2023-01-27 14:48:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [346] => WP_Post Object
                        (
                            [ID] => 3908
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:20:09
                            [post_date_gmt] => 2021-11-22 13:20:09
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:24
                            [post_modified_gmt] => 2023-01-27 14:48:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [347] => WP_Post Object
                        (
                            [ID] => 3907
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:07:49
                            [post_date_gmt] => 2021-11-22 13:07:49
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:44
                            [post_modified_gmt] => 2023-01-27 14:48:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [348] => WP_Post Object
                        (
                            [ID] => 3906
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:57:50
                            [post_date_gmt] => 2021-11-22 12:57:50
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:01
                            [post_modified_gmt] => 2023-01-27 14:49:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3906
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [349] => WP_Post Object
                        (
                            [ID] => 3904
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:20:20
                            [post_date_gmt] => 2021-11-22 12:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:47:28
                            [post_modified_gmt] => 2023-01-27 14:47:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3904
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [350] => WP_Post Object
                        (
                            [ID] => 3903
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:04:07
                            [post_date_gmt] => 2021-11-22 12:04:07
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:54
                            [post_modified_gmt] => 2023-01-27 14:49:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3903
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [351] => WP_Post Object
                        (
                            [ID] => 3901
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:42:55
                            [post_date_gmt] => 2021-11-22 11:42:55
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:50:40
                            [post_modified_gmt] => 2023-01-27 14:50:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3901
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [352] => WP_Post Object
                        (
                            [ID] => 3900
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:35:10
                            [post_date_gmt] => 2021-11-22 11:35:10
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:51:19
                            [post_modified_gmt] => 2023-01-27 14:51:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3900
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [353] => WP_Post Object
                        (
                            [ID] => 3899
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:24:36
                            [post_date_gmt] => 2021-11-22 11:24:36
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-02-03 13:42:07
                            [post_modified_gmt] => 2023-02-03 13:42:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3899
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [354] => WP_Post Object
                        (
                            [ID] => 3898
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:02:44
                            [post_date_gmt] => 2021-11-22 11:02:44
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:13
                            [post_modified_gmt] => 2023-01-27 14:52:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3898
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [355] => WP_Post Object
                        (
                            [ID] => 3897
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:34:34
                            [post_date_gmt] => 2021-11-22 10:34:34
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:36
                            [post_modified_gmt] => 2023-01-27 14:52:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3897
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [356] => WP_Post Object
                        (
                            [ID] => 3896
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:27:28
                            [post_date_gmt] => 2021-11-22 10:27:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:57
                            [post_modified_gmt] => 2023-01-27 14:52:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3896
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [357] => WP_Post Object
                        (
                            [ID] => 3895
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:20:20
                            [post_date_gmt] => 2021-11-22 10:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-30 14:09:25
                            [post_modified_gmt] => 2023-03-30 14:09:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3895
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [358] => WP_Post Object
                        (
                            [ID] => 3892
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:53:26
                            [post_date_gmt] => 2021-11-19 13:53:26
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 08:10:07
                            [post_modified_gmt] => 2023-05-05 08:10:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [359] => WP_Post Object
                        (
                            [ID] => 3891
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:11:12
                            [post_date_gmt] => 2021-11-19 13:11:12
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:54:03
                            [post_modified_gmt] => 2023-01-27 14:54:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3891
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [360] => WP_Post Object
                        (
                            [ID] => 3418
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:06:19
                            [post_date_gmt] => 2021-06-30 19:06:19
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 15:09:54
                            [post_modified_gmt] => 2023-04-04 15:09:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3418
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [361] => WP_Post Object
                        (
                            [ID] => 3417
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:04:34
                            [post_date_gmt] => 2021-06-30 19:04:34
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 15:11:09
                            [post_modified_gmt] => 2023-04-04 15:11:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3417
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [362] => WP_Post Object
                        (
                            [ID] => 3416
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:02:19
                            [post_date_gmt] => 2021-06-30 19:02:19
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:26:15
                            [post_modified_gmt] => 2023-01-04 15:26:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3416
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [363] => WP_Post Object
                        (
                            [ID] => 3415
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:00:20
                            [post_date_gmt] => 2021-06-30 19:00:20
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 15:10:10
                            [post_modified_gmt] => 2023-04-04 15:10:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3415
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [364] => WP_Post Object
                        (
                            [ID] => 3414
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:54:43
                            [post_date_gmt] => 2021-06-30 18:54:43
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-27 12:29:49
                            [post_modified_gmt] => 2022-06-27 12:29:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3414
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [365] => WP_Post Object
                        (
                            [ID] => 3413
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:52:08
                            [post_date_gmt] => 2021-06-30 18:52:08
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:38:01
                            [post_modified_gmt] => 2022-10-12 13:38:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3413
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [366] => WP_Post Object
                        (
                            [ID] => 3412
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:48:13
                            [post_date_gmt] => 2021-06-30 18:48:13
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 15:10:17
                            [post_modified_gmt] => 2023-04-04 15:10:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3412
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [367] => WP_Post Object
                        (
                            [ID] => 3411
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:39:53
                            [post_date_gmt] => 2021-06-30 18:39:53
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:30:27
                            [post_modified_gmt] => 2022-07-13 13:30:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3411
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [368] => WP_Post Object
                        (
                            [ID] => 3410
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:37:02
                            [post_date_gmt] => 2021-06-30 18:37:02
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:49:51
                            [post_modified_gmt] => 2022-12-14 15:49:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3410
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [369] => WP_Post Object
                        (
                            [ID] => 3406
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:25:58
                            [post_date_gmt] => 2021-06-30 18:25:58
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-04 15:10:36
                            [post_modified_gmt] => 2023-04-04 15:10:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [370] => WP_Post Object
                        (
                            [ID] => 3304
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:30:56
                            [post_date_gmt] => 2021-06-30 09:30:56
                            [post_content] => 
                            [post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:44:28
                            [post_modified_gmt] => 2022-12-15 16:44:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3304
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [371] => WP_Post Object
                        (
                            [ID] => 2873
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:17:08
                            [post_date_gmt] => 2021-05-11 15:17:08
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:47:07
                            [post_modified_gmt] => 2022-12-16 13:47:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [372] => WP_Post Object
                        (
                            [ID] => 2872
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:14:24
                            [post_date_gmt] => 2021-05-11 15:14:24
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:53:55
                            [post_modified_gmt] => 2022-07-13 09:53:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2872
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [373] => WP_Post Object
                        (
                            [ID] => 2870
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:07:59
                            [post_date_gmt] => 2021-05-11 15:07:59
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-15 09:15:21
                            [post_modified_gmt] => 2021-06-15 09:15:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [374] => WP_Post Object
                        (
                            [ID] => 2869
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:53:04
                            [post_date_gmt] => 2021-05-11 14:53:04
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:28:07
                            [post_modified_gmt] => 2023-05-01 14:28:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [375] => WP_Post Object
                        (
                            [ID] => 2867
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:28:02
                            [post_date_gmt] => 2021-05-11 14:28:02
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2867
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:25:53
                            [post_modified_gmt] => 2023-04-27 11:25:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 376
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 9090
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:46:30
                    [post_date_gmt] => 2023-03-08 10:46:30
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:14:44
                    [post_modified_gmt] => 2023-03-08 11:14:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9090
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 376
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => eb36459375515ce8abf3ed713ca22100
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 9090
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:46:30
                    [post_date_gmt] => 2023-03-08 10:46:30
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:14:44
                    [post_modified_gmt] => 2023-03-08 11:14:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9090
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 9089
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:34:53
                    [post_date_gmt] => 2023-03-08 10:34:53
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:24:52
                    [post_modified_gmt] => 2023-03-08 11:24:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9089
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 9088
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:31:00
                    [post_date_gmt] => 2023-03-08 10:31:00
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 10:31:00
                    [post_modified_gmt] => 2023-03-08 10:31:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9088
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 9087
                    [post_author] => 5
                    [post_date] => 2023-03-08 10:15:07
                    [post_date_gmt] => 2023-03-08 10:15:07
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 10:15:07
                    [post_modified_gmt] => 2023-03-08 10:15:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9087
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 9086
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:59:11
                    [post_date_gmt] => 2023-03-08 09:59:11
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:16:01
                    [post_modified_gmt] => 2023-03-08 12:16:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9086
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 9083
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:45:42
                    [post_date_gmt] => 2023-03-08 09:45:42
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:15:35
                    [post_modified_gmt] => 2023-03-08 11:15:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 9082
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:34:23
                    [post_date_gmt] => 2023-03-08 09:34:23
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:17:32
                    [post_modified_gmt] => 2023-03-08 11:17:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9082
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 9081
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:59:57
                    [post_date_gmt] => 2023-03-07 14:59:57
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:19:49
                    [post_modified_gmt] => 2023-03-08 11:19:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9081
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 9080
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:44:45
                    [post_date_gmt] => 2023-03-07 14:44:45
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:20:27
                    [post_modified_gmt] => 2023-03-08 11:20:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9080
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 9079
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:40:00
                    [post_date_gmt] => 2023-03-07 14:40:00
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:33:10
                    [post_modified_gmt] => 2023-05-01 14:33:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9079
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 9078
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:31:51
                    [post_date_gmt] => 2023-03-07 14:31:51
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:23:22
                    [post_modified_gmt] => 2023-03-08 11:23:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9078
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 9077
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:28:57
                    [post_date_gmt] => 2023-03-07 14:28:57
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:21:30
                    [post_modified_gmt] => 2023-03-08 11:21:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9077
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 9076
                    [post_author] => 5
                    [post_date] => 2023-03-07 14:09:37
                    [post_date_gmt] => 2023-03-07 14:09:37
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:22:36
                    [post_modified_gmt] => 2023-03-08 11:22:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9076
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 9073
                    [post_author] => 5
                    [post_date] => 2023-03-07 12:46:52
                    [post_date_gmt] => 2023-03-07 12:46:52
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:18:23
                    [post_modified_gmt] => 2023-03-08 12:18:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9073
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 9072
                    [post_author] => 5
                    [post_date] => 2023-03-07 12:24:17
                    [post_date_gmt] => 2023-03-07 12:24:17
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:19:29
                    [post_modified_gmt] => 2023-03-08 12:19:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9072
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 9071
                    [post_author] => 5
                    [post_date] => 2023-03-07 12:09:50
                    [post_date_gmt] => 2023-03-07 12:09:50
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:16:59
                    [post_modified_gmt] => 2023-03-08 12:16:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9071
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 9070
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:39:51
                    [post_date_gmt] => 2023-03-06 18:39:51
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:16:23
                    [post_modified_gmt] => 2023-03-08 12:16:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9070
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 9069
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:34:47
                    [post_date_gmt] => 2023-03-06 18:34:47
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:15:26
                    [post_modified_gmt] => 2023-03-08 12:15:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9069
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 9068
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:20:18
                    [post_date_gmt] => 2023-03-06 18:20:18
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:35:08
                    [post_modified_gmt] => 2023-03-08 11:35:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 9067
                    [post_author] => 5
                    [post_date] => 2023-03-06 16:40:37
                    [post_date_gmt] => 2023-03-06 16:40:37
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:36:48
                    [post_modified_gmt] => 2023-03-08 11:36:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9067
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 9066
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:55:39
                    [post_date_gmt] => 2023-03-06 15:55:39
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:38:10
                    [post_modified_gmt] => 2023-03-08 11:38:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9066
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 9065
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:36:15
                    [post_date_gmt] => 2023-03-06 15:36:15
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:13:07
                    [post_modified_gmt] => 2023-03-08 12:13:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9065
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 9064
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:24:23
                    [post_date_gmt] => 2023-03-06 15:24:23
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:32:16
                    [post_modified_gmt] => 2023-05-01 14:32:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9064
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 9063
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:10:08
                    [post_date_gmt] => 2023-03-06 15:10:08
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:14:56
                    [post_modified_gmt] => 2023-03-08 12:14:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9063
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 9062
                    [post_author] => 5
                    [post_date] => 2023-03-06 15:05:13
                    [post_date_gmt] => 2023-03-06 15:05:13
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 11:33:55
                    [post_modified_gmt] => 2023-03-08 11:33:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9062
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 9061
                    [post_author] => 5
                    [post_date] => 2023-03-06 13:14:19
                    [post_date_gmt] => 2023-03-06 13:14:19
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-08 12:14:30
                    [post_modified_gmt] => 2023-03-08 12:14:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9061
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 8462
                    [post_author] => 5
                    [post_date] => 2023-01-10 12:12:52
                    [post_date_gmt] => 2023-01-10 12:12:52
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-29 08:30:22
                    [post_modified_gmt] => 2023-03-29 08:30:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 8447
                    [post_author] => 5
                    [post_date] => 2022-12-15 15:33:22
                    [post_date_gmt] => 2022-12-15 15:33:22
                    [post_content] => 
                    [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-15 15:33:22
                    [post_modified_gmt] => 2022-12-15 15:33:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8447
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 3910
                    [post_author] => 5
                    [post_date] => 2022-12-15 14:44:16
                    [post_date_gmt] => 2022-12-15 14:44:16
                    [post_content] => 
                    [post_title] => Merck – MPP, Molnupiravir License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => msd-mpp-molnupiravir-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-21 15:31:00
                    [post_modified_gmt] => 2023-04-21 15:31:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3910
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 8314
                    [post_author] => 5
                    [post_date] => 2022-12-13 11:46:36
                    [post_date_gmt] => 2022-12-13 11:46:36
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-27 13:02:14
                    [post_modified_gmt] => 2023-04-27 13:02:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 8313
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:48:56
                    [post_date_gmt] => 2022-12-13 10:48:56
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-13 10:48:56
                    [post_modified_gmt] => 2022-12-13 10:48:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 8312
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:35:08
                    [post_date_gmt] => 2022-12-13 10:35:08
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-30 14:46:26
                    [post_modified_gmt] => 2023-03-30 14:46:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 8311
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:09:44
                    [post_date_gmt] => 2022-12-13 10:09:44
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-30 14:43:46
                    [post_modified_gmt] => 2023-03-30 14:43:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 8192
                    [post_author] => 5
                    [post_date] => 2022-12-13 09:04:26
                    [post_date_gmt] => 2022-12-13 09:04:26
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-13 09:05:52
                    [post_modified_gmt] => 2022-12-13 09:05:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 8191
                    [post_author] => 5
                    [post_date] => 2022-12-12 16:19:19
                    [post_date_gmt] => 2022-12-12 16:19:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-13 12:55:07
                    [post_modified_gmt] => 2022-12-13 12:55:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 8190
                    [post_author] => 5
                    [post_date] => 2022-12-12 15:29:46
                    [post_date_gmt] => 2022-12-12 15:29:46
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-14 13:05:30
                    [post_modified_gmt] => 2022-12-14 13:05:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 8157
                    [post_author] => 5
                    [post_date] => 2022-12-12 15:23:50
                    [post_date_gmt] => 2022-12-12 15:23:50
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-04 16:01:23
                    [post_modified_gmt] => 2023-04-04 16:01:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 8152
                    [post_author] => 5
                    [post_date] => 2022-12-12 12:04:21
                    [post_date_gmt] => 2022-12-12 12:04:21
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-13 12:56:37
                    [post_modified_gmt] => 2022-12-13 12:56:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 8151
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:56:08
                    [post_date_gmt] => 2022-12-12 11:56:08
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-04 16:02:18
                    [post_modified_gmt] => 2023-04-04 16:02:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 8150
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:21:26
                    [post_date_gmt] => 2022-12-12 11:21:26
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-12 11:48:09
                    [post_modified_gmt] => 2022-12-12 11:48:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 8143
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:10:19
                    [post_date_gmt] => 2022-12-12 11:10:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-12 11:10:19
                    [post_modified_gmt] => 2022-12-12 11:10:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 8142
                    [post_author] => 5
                    [post_date] => 2022-12-12 10:40:31
                    [post_date_gmt] => 2022-12-12 10:40:31
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-13 12:57:50
                    [post_modified_gmt] => 2022-12-13 12:57:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 8131
                    [post_author] => 5
                    [post_date] => 2022-12-12 09:57:36
                    [post_date_gmt] => 2022-12-12 09:57:36
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:38:50
                    [post_modified_gmt] => 2023-04-28 13:38:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 8130
                    [post_author] => 5
                    [post_date] => 2022-12-12 09:34:49
                    [post_date_gmt] => 2022-12-12 09:34:49
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-30 14:45:50
                    [post_modified_gmt] => 2023-03-30 14:45:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 8129
                    [post_author] => 5
                    [post_date] => 2022-12-12 08:55:53
                    [post_date_gmt] => 2022-12-12 08:55:53
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-05 13:48:02
                    [post_modified_gmt] => 2023-05-05 13:48:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 8051
                    [post_author] => 5
                    [post_date] => 2022-12-12 08:39:19
                    [post_date_gmt] => 2022-12-12 08:39:19
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 13:54:45
                    [post_modified_gmt] => 2023-01-10 13:54:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 5808
                    [post_author] => 5
                    [post_date] => 2022-10-04 10:04:03
                    [post_date_gmt] => 2022-10-04 10:04:03
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-04 10:04:03
                    [post_modified_gmt] => 2022-10-04 10:04:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5808
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 5782
                    [post_author] => 5
                    [post_date] => 2022-09-16 07:28:56
                    [post_date_gmt] => 2022-09-16 07:28:56
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-30 14:42:10
                    [post_modified_gmt] => 2023-03-30 14:42:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 5653
                    [post_author] => 5
                    [post_date] => 2022-08-25 12:56:30
                    [post_date_gmt] => 2022-08-25 12:56:30
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-30 14:41:50
                    [post_modified_gmt] => 2023-03-30 14:41:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 5652
                    [post_author] => 5
                    [post_date] => 2022-08-25 12:26:53
                    [post_date_gmt] => 2022-08-25 12:26:53
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 11:46:10
                    [post_modified_gmt] => 2023-01-10 11:46:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 5620
                    [post_author] => 5
                    [post_date] => 2022-08-12 12:05:12
                    [post_date_gmt] => 2022-08-12 12:05:12
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 12:05:12
                    [post_modified_gmt] => 2022-08-12 12:05:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5620
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 5619
                    [post_author] => 5
                    [post_date] => 2022-08-12 12:02:21
                    [post_date_gmt] => 2022-08-12 12:02:21
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 12:48:01
                    [post_modified_gmt] => 2022-10-12 12:48:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5619
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 5618
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:52:17
                    [post_date_gmt] => 2022-08-12 11:52:17
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:52:17
                    [post_modified_gmt] => 2022-08-12 11:52:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5618
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 5617
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:49:46
                    [post_date_gmt] => 2022-08-12 11:49:46
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:49:46
                    [post_modified_gmt] => 2022-08-12 11:49:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5617
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 5616
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:45:22
                    [post_date_gmt] => 2022-08-12 11:45:22
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:45:22
                    [post_modified_gmt] => 2022-08-12 11:45:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5616
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 5615
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:40:08
                    [post_date_gmt] => 2022-08-12 11:40:08
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 11:40:08
                    [post_modified_gmt] => 2022-08-12 11:40:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5615
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 5614
                    [post_author] => 5
                    [post_date] => 2022-08-12 11:34:41
                    [post_date_gmt] => 2022-08-12 11:34:41
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 11:28:05
                    [post_modified_gmt] => 2022-09-29 11:28:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5614
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 5612
                    [post_author] => 5
                    [post_date] => 2022-08-12 10:14:31
                    [post_date_gmt] => 2022-08-12 10:14:31
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-14 13:42:46
                    [post_modified_gmt] => 2022-12-14 13:42:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5612
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 5611
                    [post_author] => 5
                    [post_date] => 2022-08-12 10:05:33
                    [post_date_gmt] => 2022-08-12 10:05:33
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 10:05:33
                    [post_modified_gmt] => 2022-08-12 10:05:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5611
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 5610
                    [post_author] => 5
                    [post_date] => 2022-08-12 09:31:00
                    [post_date_gmt] => 2022-08-12 09:31:00
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-28 14:10:06
                    [post_modified_gmt] => 2023-03-28 14:10:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5610
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 5609
                    [post_author] => 5
                    [post_date] => 2022-08-12 09:24:43
                    [post_date_gmt] => 2022-08-12 09:24:43
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-12 09:24:43
                    [post_modified_gmt] => 2022-08-12 09:24:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5609
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 5608
                    [post_author] => 5
                    [post_date] => 2022-08-12 09:09:54
                    [post_date_gmt] => 2022-08-12 09:09:54
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-27 08:36:41
                    [post_modified_gmt] => 2023-04-27 08:36:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5608
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 5599
                    [post_author] => 5
                    [post_date] => 2022-08-11 14:17:45
                    [post_date_gmt] => 2022-08-11 14:17:45
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:23:07
                    [post_modified_gmt] => 2023-05-01 14:23:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5599
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 5596
                    [post_author] => 5
                    [post_date] => 2022-08-11 12:52:07
                    [post_date_gmt] => 2022-08-11 12:52:07
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-11-08 18:52:16
                    [post_modified_gmt] => 2022-11-08 18:52:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5596
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 5595
                    [post_author] => 5
                    [post_date] => 2022-08-11 12:36:15
                    [post_date_gmt] => 2022-08-11 12:36:15
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 12:36:15
                    [post_modified_gmt] => 2022-08-11 12:36:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5595
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 5594
                    [post_author] => 5
                    [post_date] => 2022-08-11 12:13:32
                    [post_date_gmt] => 2022-08-11 12:13:32
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:22:41
                    [post_modified_gmt] => 2023-05-01 14:22:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5594
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 5593
                    [post_author] => 5
                    [post_date] => 2022-08-11 11:48:52
                    [post_date_gmt] => 2022-08-11 11:48:52
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 12:26:53
                    [post_modified_gmt] => 2022-08-11 12:26:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5593
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 5592
                    [post_author] => 5
                    [post_date] => 2022-08-11 11:16:19
                    [post_date_gmt] => 2022-08-11 11:16:19
                    [post_content] => 
                    [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-13 13:12:08
                    [post_modified_gmt] => 2022-10-13 13:12:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5592
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 5591
                    [post_author] => 5
                    [post_date] => 2022-08-11 10:18:46
                    [post_date_gmt] => 2022-08-11 10:18:46
                    [post_content] => 
                    [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-08-11 10:18:46
                    [post_modified_gmt] => 2022-08-11 10:18:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5591
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 5429
                    [post_author] => 5
                    [post_date] => 2022-07-25 06:51:00
                    [post_date_gmt] => 2022-07-25 06:51:00
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-04 12:00:45
                    [post_modified_gmt] => 2023-05-04 12:00:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5429
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 5123
                    [post_author] => 5
                    [post_date] => 2022-06-29 15:28:35
                    [post_date_gmt] => 2022-06-29 15:28:35
                    [post_content] => 
                    [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:27:11
                    [post_modified_gmt] => 2023-04-05 12:27:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5123
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 5122
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:42:34
                    [post_date_gmt] => 2022-06-29 14:42:34
                    [post_content] => 
                    [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 5122
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 11:03:44
                    [post_modified_gmt] => 2022-10-12 11:03:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5122
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 5121
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:38:19
                    [post_date_gmt] => 2022-06-29 14:38:19
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:21:33
                    [post_modified_gmt] => 2023-04-05 12:21:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5121
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 5120
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:30:21
                    [post_date_gmt] => 2022-06-29 14:30:21
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-29 14:30:21
                    [post_modified_gmt] => 2022-06-29 14:30:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5120
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 5119
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:09:28
                    [post_date_gmt] => 2022-06-29 14:09:28
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-29 14:09:28
                    [post_modified_gmt] => 2022-06-29 14:09:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5119
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 5118
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:05:52
                    [post_date_gmt] => 2022-06-29 14:05:52
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:21:18
                    [post_modified_gmt] => 2023-04-05 12:21:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5118
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 5117
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:02:42
                    [post_date_gmt] => 2022-06-29 14:02:42
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-29 14:02:42
                    [post_modified_gmt] => 2022-06-29 14:02:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5117
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 5116
                    [post_author] => 5
                    [post_date] => 2022-06-29 14:00:58
                    [post_date_gmt] => 2022-06-29 14:00:58
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-29 14:00:58
                    [post_modified_gmt] => 2022-06-29 14:00:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5116
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 5115
                    [post_author] => 5
                    [post_date] => 2022-06-29 13:52:08
                    [post_date_gmt] => 2022-06-29 13:52:08
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 12:48:53
                    [post_modified_gmt] => 2022-10-12 12:48:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5115
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 5114
                    [post_author] => 5
                    [post_date] => 2022-06-29 13:46:01
                    [post_date_gmt] => 2022-06-29 13:46:01
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-29 15:10:31
                    [post_modified_gmt] => 2022-06-29 15:10:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5114
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 5113
                    [post_author] => 5
                    [post_date] => 2022-06-29 13:33:56
                    [post_date_gmt] => 2022-06-29 13:33:56
                    [post_content] => 
                    [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-21 12:38:36
                    [post_modified_gmt] => 2023-03-21 12:38:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5113
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 5112
                    [post_author] => 5
                    [post_date] => 2022-06-29 13:04:55
                    [post_date_gmt] => 2022-06-29 13:04:55
                    [post_content] => 
                    [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 13:33:12
                    [post_modified_gmt] => 2022-07-13 13:33:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5112
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 5111
                    [post_author] => 5
                    [post_date] => 2022-06-29 12:40:35
                    [post_date_gmt] => 2022-06-29 12:40:35
                    [post_content] => 
                    [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:19:57
                    [post_modified_gmt] => 2023-04-05 12:19:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5111
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 4808
                    [post_author] => 5
                    [post_date] => 2022-05-24 09:09:54
                    [post_date_gmt] => 2022-05-24 09:09:54
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:40:46
                    [post_modified_gmt] => 2023-04-28 13:40:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4808
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 4807
                    [post_author] => 5
                    [post_date] => 2022-05-24 09:02:55
                    [post_date_gmt] => 2022-05-24 09:02:55
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-24 09:02:55
                    [post_modified_gmt] => 2022-05-24 09:02:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4807
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 4806
                    [post_author] => 5
                    [post_date] => 2022-05-24 08:59:08
                    [post_date_gmt] => 2022-05-24 08:59:08
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:40:29
                    [post_modified_gmt] => 2023-04-28 13:40:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4806
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 4805
                    [post_author] => 5
                    [post_date] => 2022-05-24 08:53:12
                    [post_date_gmt] => 2022-05-24 08:53:12
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-24 08:59:42
                    [post_modified_gmt] => 2022-05-24 08:59:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4805
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 4804
                    [post_author] => 5
                    [post_date] => 2022-05-24 08:40:15
                    [post_date_gmt] => 2022-05-24 08:40:15
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-24 08:53:51
                    [post_modified_gmt] => 2022-05-24 08:53:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4804
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 4802
                    [post_author] => 5
                    [post_date] => 2022-05-24 08:24:23
                    [post_date_gmt] => 2022-05-24 08:24:23
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-24 08:24:23
                    [post_modified_gmt] => 2022-05-24 08:24:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4802
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 4801
                    [post_author] => 5
                    [post_date] => 2022-05-24 08:19:21
                    [post_date_gmt] => 2022-05-24 08:19:21
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:40:03
                    [post_modified_gmt] => 2023-04-28 13:40:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4801
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 4800
                    [post_author] => 5
                    [post_date] => 2022-05-24 08:07:39
                    [post_date_gmt] => 2022-05-24 08:07:39
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 12:53:27
                    [post_modified_gmt] => 2022-10-12 12:53:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4800
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 4798
                    [post_author] => 5
                    [post_date] => 2022-05-23 14:11:13
                    [post_date_gmt] => 2022-05-23 14:11:13
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-02-03 13:36:05
                    [post_modified_gmt] => 2023-02-03 13:36:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4798
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 4797
                    [post_author] => 5
                    [post_date] => 2022-05-23 13:54:57
                    [post_date_gmt] => 2022-05-23 13:54:57
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 12:28:31
                    [post_modified_gmt] => 2022-07-13 12:28:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4797
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 4796
                    [post_author] => 5
                    [post_date] => 2022-05-23 13:54:05
                    [post_date_gmt] => 2022-05-23 13:54:05
                    [post_content] => 
                    [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:39:34
                    [post_modified_gmt] => 2023-04-28 13:39:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4796
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 4661
                    [post_author] => 5
                    [post_date] => 2022-04-20 08:13:06
                    [post_date_gmt] => 2022-04-20 08:13:06
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-03 13:53:17
                    [post_modified_gmt] => 2022-10-03 13:53:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 4147
                    [post_author] => 5
                    [post_date] => 2022-04-18 12:53:51
                    [post_date_gmt] => 2022-04-18 12:53:51
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-15 16:24:43
                    [post_modified_gmt] => 2022-12-15 16:24:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 4601
                    [post_author] => 5
                    [post_date] => 2022-04-18 10:40:48
                    [post_date_gmt] => 2022-04-18 10:40:48
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 10:44:46
                    [post_modified_gmt] => 2022-04-18 10:44:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4601
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 4148
                    [post_author] => 5
                    [post_date] => 2022-04-12 08:59:45
                    [post_date_gmt] => 2022-04-12 08:59:45
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:25:17
                    [post_modified_gmt] => 2023-05-01 14:25:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 4223
                    [post_author] => 5
                    [post_date] => 2022-03-04 09:43:58
                    [post_date_gmt] => 2022-03-04 09:43:58
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-31 18:00:18
                    [post_modified_gmt] => 2022-05-31 18:00:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4223
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 4222
                    [post_author] => 5
                    [post_date] => 2022-03-04 09:14:41
                    [post_date_gmt] => 2022-03-04 09:14:41
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 11:13:06
                    [post_modified_gmt] => 2022-10-12 11:13:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4222
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 4221
                    [post_author] => 5
                    [post_date] => 2022-03-04 09:05:29
                    [post_date_gmt] => 2022-03-04 09:05:29
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-26 14:36:15
                    [post_modified_gmt] => 2022-09-26 14:36:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 4220
                    [post_author] => 5
                    [post_date] => 2022-03-04 08:47:04
                    [post_date_gmt] => 2022-03-04 08:47:04
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:22:53
                    [post_modified_gmt] => 2023-04-28 13:22:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4220
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 4219
                    [post_author] => 5
                    [post_date] => 2022-03-04 08:02:15
                    [post_date_gmt] => 2022-03-04 08:02:15
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-04 15:55:41
                    [post_modified_gmt] => 2023-01-04 15:55:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4219
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 4218
                    [post_author] => 5
                    [post_date] => 2022-03-03 14:17:53
                    [post_date_gmt] => 2022-03-03 14:17:53
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-04 15:10:14
                    [post_modified_gmt] => 2023-01-04 15:10:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 4217
                    [post_author] => 5
                    [post_date] => 2022-03-03 13:59:58
                    [post_date_gmt] => 2022-03-03 13:59:58
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-31 17:56:43
                    [post_modified_gmt] => 2022-05-31 17:56:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4217
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 4216
                    [post_author] => 5
                    [post_date] => 2022-03-03 13:45:21
                    [post_date_gmt] => 2022-03-03 13:45:21
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-31 17:56:00
                    [post_modified_gmt] => 2022-05-31 17:56:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4216
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 4215
                    [post_author] => 5
                    [post_date] => 2022-03-03 13:31:56
                    [post_date_gmt] => 2022-03-03 13:31:56
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 10:41:55
                    [post_modified_gmt] => 2022-09-29 10:41:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4215
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 4214
                    [post_author] => 5
                    [post_date] => 2022-03-03 12:54:33
                    [post_date_gmt] => 2022-03-03 12:54:33
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:21:12
                    [post_modified_gmt] => 2023-04-28 13:21:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4214
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 4213
                    [post_author] => 5
                    [post_date] => 2022-03-03 10:54:01
                    [post_date_gmt] => 2022-03-03 10:54:01
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-05-31 15:05:32
                    [post_modified_gmt] => 2022-05-31 15:05:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4213
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 4212
                    [post_author] => 5
                    [post_date] => 2022-03-02 14:54:16
                    [post_date_gmt] => 2022-03-02 14:54:16
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:20:51
                    [post_modified_gmt] => 2023-04-28 13:20:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4212
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 4210
                    [post_author] => 5
                    [post_date] => 2022-03-02 13:14:31
                    [post_date_gmt] => 2022-03-02 13:14:31
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 12:03:49
                    [post_modified_gmt] => 2022-07-13 12:03:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4210
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 4209
                    [post_author] => 5
                    [post_date] => 2022-03-02 12:07:13
                    [post_date_gmt] => 2022-03-02 12:07:13
                    [post_content] => 
                    [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-13 13:16:54
                    [post_modified_gmt] => 2022-10-13 13:16:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4209
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 4205
                    [post_author] => 5
                    [post_date] => 2022-02-28 15:24:19
                    [post_date_gmt] => 2022-02-28 15:24:19
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 12:59:13
                    [post_modified_gmt] => 2022-10-12 12:59:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 4204
                    [post_author] => 5
                    [post_date] => 2022-02-28 14:53:11
                    [post_date_gmt] => 2022-02-28 14:53:11
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-14 13:07:32
                    [post_modified_gmt] => 2022-12-14 13:07:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 4201
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:33:22
                    [post_date_gmt] => 2022-02-28 13:33:22
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 13:13:57
                    [post_modified_gmt] => 2023-01-10 13:13:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 4200
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:13:29
                    [post_date_gmt] => 2022-02-28 13:13:29
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 11:13:52
                    [post_modified_gmt] => 2022-10-12 11:13:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 4161
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:48:58
                    [post_date_gmt] => 2022-02-02 13:48:58
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-15 09:53:28
                    [post_modified_gmt] => 2022-12-15 09:53:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 4159
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:10:48
                    [post_date_gmt] => 2022-02-02 13:10:48
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 11:15:11
                    [post_modified_gmt] => 2022-10-12 11:15:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 4158
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:00:08
                    [post_date_gmt] => 2022-02-02 13:00:08
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-03 12:48:45
                    [post_modified_gmt] => 2023-01-03 12:48:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 4157
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:54:56
                    [post_date_gmt] => 2022-02-02 12:54:56
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:13:37
                    [post_modified_gmt] => 2022-04-18 13:13:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 4156
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:36:42
                    [post_date_gmt] => 2022-02-02 12:36:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-04 15:10:37
                    [post_modified_gmt] => 2023-01-04 15:10:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 4155
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:19:16
                    [post_date_gmt] => 2022-02-02 12:19:16
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:12:26
                    [post_modified_gmt] => 2022-04-18 13:12:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 4154
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:13:41
                    [post_date_gmt] => 2022-02-02 12:13:41
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-02 12:13:41
                    [post_modified_gmt] => 2022-02-02 12:13:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [123] => WP_Post Object
                (
                    [ID] => 4153
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:10:13
                    [post_date_gmt] => 2022-02-02 12:10:13
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 11:28:28
                    [post_modified_gmt] => 2022-09-29 11:28:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [124] => WP_Post Object
                (
                    [ID] => 4152
                    [post_author] => 5
                    [post_date] => 2022-02-02 11:51:54
                    [post_date_gmt] => 2022-02-02 11:51:54
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-26 14:57:07
                    [post_modified_gmt] => 2022-09-26 14:57:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [125] => WP_Post Object
                (
                    [ID] => 4151
                    [post_author] => 5
                    [post_date] => 2022-02-02 11:39:24
                    [post_date_gmt] => 2022-02-02 11:39:24
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-12 13:00:22
                    [post_modified_gmt] => 2022-10-12 13:00:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [126] => WP_Post Object
                (
                    [ID] => 4150
                    [post_author] => 5
                    [post_date] => 2022-02-02 10:24:30
                    [post_date_gmt] => 2022-02-02 10:24:30
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:01:03
                    [post_modified_gmt] => 2022-04-18 13:01:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [127] => WP_Post Object
                (
                    [ID] => 4149
                    [post_author] => 5
                    [post_date] => 2022-02-02 10:15:42
                    [post_date_gmt] => 2022-02-02 10:15:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:24:14
                    [post_modified_gmt] => 2023-05-01 14:24:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [128] => WP_Post Object
                (
                    [ID] => 4146
                    [post_author] => 5
                    [post_date] => 2022-02-02 07:28:42
                    [post_date_gmt] => 2022-02-02 07:28:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-10-13 13:18:01
                    [post_modified_gmt] => 2022-10-13 13:18:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [129] => WP_Post Object
                (
                    [ID] => 4141
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:31:23
                    [post_date_gmt] => 2022-01-31 14:31:23
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:40:20
                    [post_modified_gmt] => 2023-01-10 10:40:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4141
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [130] => WP_Post Object
                (
                    [ID] => 4140
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:22:03
                    [post_date_gmt] => 2022-01-31 14:22:03
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:54:15
                    [post_modified_gmt] => 2023-01-10 10:54:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4140
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [131] => WP_Post Object
                (
                    [ID] => 4139
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:18:32
                    [post_date_gmt] => 2022-01-31 14:18:32
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:58:00
                    [post_modified_gmt] => 2023-01-10 10:58:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4139
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [132] => WP_Post Object
                (
                    [ID] => 4138
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:09:33
                    [post_date_gmt] => 2022-01-31 14:09:33
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:59:39
                    [post_modified_gmt] => 2023-01-10 10:59:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4138
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [133] => WP_Post Object
                (
                    [ID] => 4137
                    [post_author] => 5
                    [post_date] => 2022-01-31 13:53:37
                    [post_date_gmt] => 2022-01-31 13:53:37
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 11:02:20
                    [post_modified_gmt] => 2023-01-10 11:02:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4137
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [134] => WP_Post Object
                (
                    [ID] => 4136
                    [post_author] => 5
                    [post_date] => 2022-01-31 13:42:47
                    [post_date_gmt] => 2022-01-31 13:42:47
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 11:01:51
                    [post_modified_gmt] => 2023-01-10 11:01:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4136
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [135] => WP_Post Object
                (
                    [ID] => 4135
                    [post_author] => 5
                    [post_date] => 2022-01-31 13:25:08
                    [post_date_gmt] => 2022-01-31 13:25:08
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:59:11
                    [post_modified_gmt] => 2023-01-10 10:59:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4135
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [136] => WP_Post Object
                (
                    [ID] => 4134
                    [post_author] => 5
                    [post_date] => 2022-01-31 12:56:28
                    [post_date_gmt] => 2022-01-31 12:56:28
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:58:24
                    [post_modified_gmt] => 2023-01-10 10:58:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4134
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [137] => WP_Post Object
                (
                    [ID] => 4133
                    [post_author] => 5
                    [post_date] => 2022-01-31 12:22:56
                    [post_date_gmt] => 2022-01-31 12:22:56
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:56:11
                    [post_modified_gmt] => 2023-01-10 10:56:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4133
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [138] => WP_Post Object
                (
                    [ID] => 4131
                    [post_author] => 5
                    [post_date] => 2022-01-29 16:21:19
                    [post_date_gmt] => 2022-01-29 16:21:19
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:35:36
                    [post_modified_gmt] => 2023-04-28 13:35:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [139] => WP_Post Object
                (
                    [ID] => 4130
                    [post_author] => 5
                    [post_date] => 2022-01-29 15:34:50
                    [post_date_gmt] => 2022-01-29 15:34:50
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 10:57:20
                    [post_modified_gmt] => 2023-01-10 10:57:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4130
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [140] => WP_Post Object
                (
                    [ID] => 4129
                    [post_author] => 5
                    [post_date] => 2022-01-28 14:43:06
                    [post_date_gmt] => 2022-01-28 14:43:06
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:34:27
                    [post_modified_gmt] => 2023-04-28 13:34:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [141] => WP_Post Object
                (
                    [ID] => 4128
                    [post_author] => 5
                    [post_date] => 2022-01-28 13:38:44
                    [post_date_gmt] => 2022-01-28 13:38:44
                    [post_content] => 
                    [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-10 11:07:15
                    [post_modified_gmt] => 2023-01-10 11:07:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4128
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [142] => WP_Post Object
                (
                    [ID] => 4058
                    [post_author] => 5
                    [post_date] => 2022-01-04 14:25:52
                    [post_date_gmt] => 2022-01-04 14:25:52
                    [post_content] => 
                    [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-03 12:47:11
                    [post_modified_gmt] => 2023-01-03 12:47:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4058
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [143] => WP_Post Object
                (
                    [ID] => 4054
                    [post_author] => 5
                    [post_date] => 2022-01-03 11:45:52
                    [post_date_gmt] => 2022-01-03 11:45:52
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-15 14:45:07
                    [post_modified_gmt] => 2022-12-15 14:45:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4054
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [144] => WP_Post Object
                (
                    [ID] => 4051
                    [post_author] => 5
                    [post_date] => 2022-01-03 11:01:41
                    [post_date_gmt] => 2022-01-03 11:01:41
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:38:45
                    [post_modified_gmt] => 2023-05-01 14:38:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4051
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [145] => WP_Post Object
                (
                    [ID] => 4050
                    [post_author] => 5
                    [post_date] => 2022-01-03 10:49:32
                    [post_date_gmt] => 2022-01-03 10:49:32
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-01-03 10:56:55
                    [post_modified_gmt] => 2022-01-03 10:56:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4050
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [146] => WP_Post Object
                (
                    [ID] => 4047
                    [post_author] => 5
                    [post_date] => 2021-12-27 17:17:36
                    [post_date_gmt] => 2021-12-27 17:17:36
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-04 16:05:43
                    [post_modified_gmt] => 2023-01-04 16:05:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4047
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [147] => WP_Post Object
                (
                    [ID] => 4046
                    [post_author] => 5
                    [post_date] => 2021-12-27 17:10:47
                    [post_date_gmt] => 2021-12-27 17:10:47
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-04 15:13:16
                    [post_modified_gmt] => 2023-01-04 15:13:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4046
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [148] => WP_Post Object
                (
                    [ID] => 4045
                    [post_author] => 5
                    [post_date] => 2021-12-27 17:07:25
                    [post_date_gmt] => 2021-12-27 17:07:25
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-27 11:30:11
                    [post_modified_gmt] => 2023-04-27 11:30:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4045
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [149] => WP_Post Object
                (
                    [ID] => 4043
                    [post_author] => 5
                    [post_date] => 2021-12-27 16:47:54
                    [post_date_gmt] => 2021-12-27 16:47:54
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-12-27 16:47:54
                    [post_modified_gmt] => 2021-12-27 16:47:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4043
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [150] => WP_Post Object
                (
                    [ID] => 4042
                    [post_author] => 5
                    [post_date] => 2021-12-27 16:41:56
                    [post_date_gmt] => 2021-12-27 16:41:56
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 12:25:56
                    [post_modified_gmt] => 2022-09-29 12:25:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4042
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [151] => WP_Post Object
                (
                    [ID] => 4041
                    [post_author] => 5
                    [post_date] => 2021-12-27 16:28:21
                    [post_date_gmt] => 2021-12-27 16:28:21
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-21 11:33:53
                    [post_modified_gmt] => 2023-03-21 11:33:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4041
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [152] => WP_Post Object
                (
                    [ID] => 4040
                    [post_author] => 5
                    [post_date] => 2021-12-27 15:24:04
                    [post_date_gmt] => 2021-12-27 15:24:04
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-21 11:34:34
                    [post_modified_gmt] => 2023-03-21 11:34:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4040
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [153] => WP_Post Object
                (
                    [ID] => 4038
                    [post_author] => 5
                    [post_date] => 2021-12-27 15:08:30
                    [post_date_gmt] => 2021-12-27 15:08:30
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:35:46
                    [post_modified_gmt] => 2023-04-05 12:35:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4038
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [154] => WP_Post Object
                (
                    [ID] => 4036
                    [post_author] => 5
                    [post_date] => 2021-12-26 17:01:45
                    [post_date_gmt] => 2021-12-26 17:01:45
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-21 11:31:29
                    [post_modified_gmt] => 2023-03-21 11:31:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4036
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [155] => WP_Post Object
                (
                    [ID] => 4035
                    [post_author] => 5
                    [post_date] => 2021-12-26 16:47:36
                    [post_date_gmt] => 2021-12-26 16:47:36
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-16 13:28:18
                    [post_modified_gmt] => 2022-12-16 13:28:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4035
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [156] => WP_Post Object
                (
                    [ID] => 4032
                    [post_author] => 5
                    [post_date] => 2021-12-26 16:32:27
                    [post_date_gmt] => 2021-12-26 16:32:27
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-05-01 14:37:25
                    [post_modified_gmt] => 2023-05-01 14:37:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4032
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [157] => WP_Post Object
                (
                    [ID] => 4029
                    [post_author] => 5
                    [post_date] => 2021-12-21 12:22:08
                    [post_date_gmt] => 2021-12-21 12:22:08
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:36:19
                    [post_modified_gmt] => 2023-04-05 12:36:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4029
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [158] => WP_Post Object
                (
                    [ID] => 4028
                    [post_author] => 5
                    [post_date] => 2021-12-21 11:55:28
                    [post_date_gmt] => 2021-12-21 11:55:28
                    [post_content] => 
                    [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 12:35:05
                    [post_modified_gmt] => 2023-04-05 12:35:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4028
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [159] => WP_Post Object
                (
                    [ID] => 4024
                    [post_author] => 5
                    [post_date] => 2021-12-15 15:33:17
                    [post_date_gmt] => 2021-12-15 15:33:17
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-12-15 15:33:17
                    [post_modified_gmt] => 2021-12-15 15:33:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4024
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [160] => WP_Post Object
                (
                    [ID] => 4022
                    [post_author] => 5
                    [post_date] => 2021-12-15 14:49:36
                    [post_date_gmt] => 2021-12-15 14:49:36
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:43:03
                    [post_modified_gmt] => 2023-04-28 13:43:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4022
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [161] => WP_Post Object
                (
                    [ID] => 4021
                    [post_author] => 5
                    [post_date] => 2021-12-15 14:31:00
                    [post_date_gmt] => 2021-12-15 14:31:00
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-21 13:06:46
                    [post_modified_gmt] => 2023-03-21 13:06:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4021
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [162] => WP_Post Object
                (
                    [ID] => 4020
                    [post_author] => 5
                    [post_date] => 2021-12-15 14:24:47
                    [post_date_gmt] => 2021-12-15 14:24:47
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-01-04 15:13:47
                    [post_modified_gmt] => 2023-01-04 15:13:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4020
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [163] => WP_Post Object
                (
                    [ID] => 4017
                    [post_author] => 5
                    [post_date] => 2021-12-15 13:22:49
                    [post_date_gmt] => 2021-12-15 13:22:49
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-12-15 13:22:49
                    [post_modified_gmt] => 2021-12-15 13:22:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4017
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [164] => WP_Post Object
                (
                    [ID] => 4016
                    [post_author] => 5
                    [post_date] => 2021-12-15 13:20:07
                    [post_date_gmt] => 2021-12-15 13:20:07
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-09-29 10:54:29
                    [post_modified_gmt] => 2022-09-29 10:54:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4016
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [165] => WP_Post Object
                (
                    [ID] => 4014
                    [post_author] => 5
                    [post_date] => 2021-12-15 12:33:09
                    [post_date_gmt] => 2021-12-15 12:33:09
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:42:36
                    [post_modified_gmt] => 2023-04-28 13:42:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4014
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [166] => WP_Post Object
                (
                    [ID] => 4013
                    [post_author] => 5
                    [post_date] => 2021-12-15 12:16:20
                    [post_date_gmt] => 2021-12-15 12:16:20
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-31 09:12:31
                    [post_modified_gmt] => 2023-03-31 09:12:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4013
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [167] => WP_Post Object
                (
                    [ID] => 4011
                    [post_author] => 5
                    [post_date] => 2021-12-14 15:21:54
                    [post_date_gmt] => 2021-12-14 15:21:54
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 09:25:12
                    [post_modified_gmt] => 2022-07-13 09:25:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4011
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [168] => WP_Post Object
                (
                    [ID] => 4009
                    [post_author] => 5
                    [post_date] => 2021-12-14 15:10:51
                    [post_date_gmt] => 2021-12-14 15:10:51
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-28 13:42:14
                    [post_modified_gmt] => 2023-04-28 13:42:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4009
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [169] => WP_Post Object
                (
                    [ID] => 4007
                    [post_author] => 5
                    [post_date] => 2021-12-14 08:51:32
                    [post_date_gmt] => 2021-12-14 08:51:32
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-12-14 08:51:44
                    [post_modified_gmt] => 2021-12-14 08:51:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4007
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [170] => WP_Post Object
                (
                    [ID] => 4006
                    [post_author] => 5
                    [post_date] => 2021-12-14 08:16:01
                    [post_date_gmt] => 2021-12-14 08:16:01
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-04-05 10:44:31
                    [post_modified_gmt] => 2023-04-05 10:44:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4006
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [171] => WP_Post Object
                (
                    [ID] => 4004
                    [post_author] => 5
                    [post_date] => 2021-12-14 07:57:41
                    [post_date_gmt] => 2021-12-14 07:57:41
                    [post_content] => 
                    [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-30 14:04:14
                    [post_modified_gmt] => 2023-03-30 14:04:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4004
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0